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The primary focus of this work was to develop new naturally derived 
hydrogel scaffolds for soft tissue engineering applications such as peripheral 
nerve repair. Ideal implants for soft tissues are degradable, porous, highly 
permeable, able to maintain a desired shape, and able to specifically modulate 
biological responses. Naturally derived materials are particularly suitable for these 
applications because they are degradable and intrinsically bioactive. As presented 
in this dissertation, we have made significant steps towards meeting these aims by 
creating new hydrogel scaffolds from crosslinked hyaluronic acid (HA).  
As a biomaterial candidate, HA presents a unique combination of 
advantages. Specifically, HA is a naturally derived, enzymatically degradable, 
non-immunogenic, non-adhesive, bioactive glycosaminoglycan that has been 
 viii
associated with several cellular processes, including angiogenesis, extracellular 
matrix homeostasis, and the regulation of inflammation.  
In our first studies, we developed a novel hydrogel tissue engineering 
scaffold from photocrosslinkable glycidyl methacrylate-modified HA (GMHA). 
The GMHA hydrogels were found to be enzymatically degradable, 
biocompatible, and the degradation products of GMHA retained a similar level of 
bioactivity as unmodified HA fragments. Further development of these GMHA 
hydrogels focused on methods to attach peptides (e.g., the fibronectin-derived cell 
adhesion sequence RGD or arg-gly-asp). Such sequences could provide a versatile 
method to control several adhesion-related cellular processes, including migration 
and proliferation. Finally, we explored GMHA-based hydrogels for controlled 
protein release.  Localized delivery of bioactive proteins such as growth factors 
provides an additional level of versatility for modulating specific cellular 
behaviors involved in tissue repair. We believe that these novel GMHA-based 
biomaterials offer unique advantages over synthetic and non-degradable 
scaffolding biomaterials and provide a solid foundation for further modification 
and use in a variety of soft tissue engineering applications. 
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Chapter 1: Introduction  
1.1 SURGICAL TREATMENTS FOR TISSUE LOSS AND ORGAN FAILURE 
Annually, several million Americans are afflicted with tissue loss or organ 
failure due to trauma or disease, resulting collectively in the most common and 
expensive challenge to today's health care system [1]. To treat this loss, surgeons 
have several options. They may transplant organs from one individual to another, 
such as the case with kidney, heart, liver, and corneal transplants. Surgeons also 
may reconstruct tissues (e.g., breast or intestinal reconstruction), graft tissue 
within one patient from one site to another (e.g., coronary artery bypass with a 
saphenous vein graft derived from the lower leg), replace the biological function 
with drug treatments (e.g., insulin and hormone therapies), or replace the 
mechanical function of a tissue with a prosthetic implant (e.g., heart valve and hip 
replacements; Figure 1.1). Finally, physicians may treat organ loss with 
mechanical devices, such as kidney dialyzers or liver assist devices, which are 
located outside of the body. 
These surgical treatments have saved many lives and can be effective 
organ and tissue replacements; however, these therapies have significant 
drawbacks. For example, donor shortages severely limit the availability of 
transplant organs. Surgical reconstruction is limited by the availability of "spare" 
tissue within the patient and can result in loss of function at the donor site or other 
long-term problems [2]. 
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Figure 1.1 Mechanical prosthetics and tissue engineering products 
In addition to transplantation and reconstructive surgery, mechanical devices can be used 
to replace or restore certain lost tissue function. For example, prosthetic devices 
constructed of metals and hard plastics are used to replace broken hips and heart valves. 
Unfortunately, these non-degradable devices have drawbacks: the prosthesis is subject to 
mechanical failure, and often long-term drug intervention is required to prevent blood 
clotting. To address these drawbacks, the field of tissue engineering aims to utilize the 
principles of engineering and the life sciences to develop new biological substitutes. 
Examples of tissue engineering products under recent development are Organogenesis' 
Apligraf skin replacement (third row, left) and Cook Biotech's Surgisis Gold Hernia 
Repair Graft (third row, right). 
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Prosthetic implants and mechanical devices, however, offer distinct 
advantages because they are composed of synthetic materials (e.g., metals, 
ceramics, plastics, glasses), which are practically unlimited in supply. Within the 
past 50 years, work in the biomedical engineering field has developed new 
materials to extend the functionality, biocompatibility, and lifespan of innovative 
device designs. Unfortunately, mechanical devices and prosthetics cannot replace 
the long-term function of a biological tissue or a complex organ and therefore do 
not completely prevent further patient deterioration.   
1.2 TISSUE ENGINEERING 
Building on the successful elements of the above-mentioned surgical 
therapies, a new field has emerged. Tissue engineering is an interdisciplinary field 
that melds the knowledge of the clinical and life sciences with engineering design 
principles to create novel methods to repair tissues, facilitate natural healing, or 
replace organ function [1,3-5]. Four general tissue engineering strategies have 
emerged: 1) transplanting cells to form new tissues at the damaged site, 2) 
implanting "bioengineered" or "bioartificial" tissues that were constructed in a 
laboratory, 3) stimulating healing or regeneration from surrounding healthy 
tissues, and 4) blocking an undesirable biological or pathological process. Table 
1.1 outlines examples of each tissue engineering strategy. 
1.3 SCAFFOLDING BIOMATERIALS AND HYDROGELS 
Each of the four tissue engineering strategies critically relies on 
biomaterial scaffolds. Scaffolds are biocompatible materials that can be porous 
and sponge-like, hydrated gels, or complex structures with aligned micron-sized  
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Table 1.1 Tissue engineering strategies  
Cell Transplantation Disease or injury addressed  Ref. 
    Dopamine neurons Parkinson's disease [6] 
    Pancreatic islet cells  Diabetes [7-9] 
   
"Bioengineered" or "Bioartificial" Tissues 
    Blood vessels Atherosclerosis, aneurysm [10,11] 
    Heart valves Malfunctioning valve [12] 
    Skin Burns, diabetic ulcers, chronic wounds [13-15] 
    Bladder Disease, cancer [16] 
    Bones Fractures, tumor removal [17,18] 
    Cartilage Arthritis [19,20] 
    Tendons Injury [21,22] 
    Ligaments Injury [23] 
    Ophthalmic Macular degeneration, cataracts [24,25] 
   
Techniques to Stimulate Healing or Regeneration 
    Peripheral nerve regeneration Severing or crush injuries [26-28] 
    Spinal cord repair Crush injuries [29,30] 
    Wound healing Burns, diabetic ulcers, chronic wounds [31] 
    Bone repair Fractures, tumor removal [32] 
   
Methods to Block an Undesirable Biological or Pathological Response 
    Coated stents and angioplasty balloons Prevent atherosclerosis  [33,34] 
    Anti-adhesive hydrogel barriers Prevent post-operative adhesions [35,36] 
   
* This list is illustrative rather than exhaustive. 
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channels or grooves [37] (see Figure 1.2). Such biomaterials must be specifically 
designed to meet the demands for each application. For example, bone scaffolds 
must be strong and stiff, blood vessel scaffolds need to be elastic and tubular, and 
scaffolds for liver regeneration must be soft and porous (Figure 1.3). 
Given such detailed criteria, it is clear that the success of each tissue 
engineering scaffold depends on the choice of the implanted biomaterial [38-42]. 
To meet the needs of demanding applications such as the guided growth of nerve, 
or the construction of a complex organ such as the heart, the scaffold material 
must provide cells with a very specific set of instructions. Therefore, an intricate 
knowledge of both the precise application as well as more general biological 
processes (e.g., inflammation, tissue rejection, and scar tissue formation) is 
required. The ideal biomaterial scaffold would promote the desired cellular 
response while minimizing any unwanted signals from the wound or disease site.  
In addition to invoking the appropriate cellular response, three 
dimensional scaffolding biomaterials must have the following physicochemical 
characteristics: (1) a high porosity to allow cell growth and the transport of 
nutrients and cellular byproducts, (2) biodegradable and bioresorbable 
components, (3) mechanical properties to match the implant site, and (4) a 
versatile and reproducible manufacturing process to allow a variety of sizes and 
shapes [41]. It is likely that no one material will satisfy all of the design 
parameters in all applications. Rather, a wide range of materials will be 
appropriate to meet the various tissue engineering applications. 
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Figure 1.2 Tissue engineering scaffolds for creating bioartificial organs 
To create a bioartificial organ, one must first design a scaffold biomaterial. The scaffold 
can be porous and sponge-like, hydrated gels, or highly complex structures with aligned 
micron-sized channels or grooves. In a laboratory, the scaffold is combined with cells and 
a mixture of essential nutrients, including specialized proteins called growth factors. The 
cells attach to and remodel the scaffold by degrading the polymer and replacing it with its 
own extracellular matrix. When the desired biological and mechanical properties are 
achieved, the bioartificial organ can be implanted into a patient. Examples of parameters 
that can affect the final organ include scaffold material and density, the presence of 
multiple cell types, growth factor gradients, and a pre-established vascular supply.  
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Figure 1.3 Classes of tissue engineering applications as a function of 
biomechanics 
Unique scaffolding biomaterials must be designed to meet the demands for each 
individual tissue application. For example, durable tissues, such as bone and cartilage, 
require strong and stiff biomaterials. Elastic tissues, such as those in the cardiovascular, 
urinary, and gastrointestinal (GI) systems as well as skin, require strength in addition to 
flexibility, and the ability to recoil following the release of stress. Soft tissue engineering 
applications, such as nerve, liver, and pancreas, require non-brittle, hydrated materials 
that are soft and yet can maintain a desired shape. Drawings are adapted from [43]. 
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In our work, we are specifically targeting soft tissue engineering 
applications, such as nerve regeneration (Figure 1.4). In such systems, the 
scaffolds must be soft, highly hydrated, porous, and degradable. In addition to 
meeting these needs, hydrogels inherently present several distinct advantages as a 
scaffolding material (outlined in Table 1.2). Hydrogels are three dimensional, 
water-swollen polymeric structures that have structural similarity to human 
extracellular matrix [44-46]. Hydrogels are formed by the physical or chemical 
crosslinking of hydrophilic polymers. These crosslinks provide a mesh-like 
structure and can be used to specifically tune the physicochemical properties of 
the scaffold. Furthermore, because hydrogels are highly hydrophilic, they are 
generally considered to be biocompatible. For all of these reasons, hydrogels have 
found a number of applications in tissue engineering (see Table 1.3).  
1.4 NATURAL HYDROGEL BIOMATERIALS 
Hydrogels from natural polymers have been widely used for tissue 
engineering applications [41,44]. Generally, naturally derived polymers (e.g., 
proteins such as collagen, gelatin and fibrin, and carbohydrates such as agarose, 
alginate, hyaluronic acid and heparin) are more biocompatible than their synthetic 
counterparts (e.g., polyethylene glycol, polyhydroxyethyl methacrylate, polyvinyl 
alcohol) because they more closely resemble native tissues. Furthermore, most 
natural polymers are biodegradable through hydrolysis or an enzymatically 
mediated process.  
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Figure 1.4 Peripheral nerve tissue engineering 
Most of the current research in our laboratory is applied to the peripheral nervous system, 
which is composed of the nerves that innervate muscle tissue and transmit sensory and 
excitatory input to and from the spinal column. We are analyzing various biomaterials 
that can be used to specifically stimulate, and guide, nerves to regrow their severed 
axons. Ultimately, nerve guidance channels (shown in the figure middle) could be used to 
aid the repair of damaged peripheral nerves, such as would be required for facial and 
hand reconstruction, and ultimately, could be used to aid the regeneration of damaged 
spinal cord. A peripheral nerve is shown in cross-section (figure adapted from [47]) and 
depicts the bundles of individual nerve fibers that make up the entire nerve cable. 
Peripheral nerves are well vascularized by capillaries within the support tissue of the 
nerve cable or by vessels that penetrate the nerve from surrounding arteries and veins.  
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Table 1.2 Advantages and disadvantages of hydrogels as scaffolding biomaterials 
Advantages 
    Hydrated environment can protect cells and some drugs (peptides, proteins, DNA) 
    Good transport of nutrient to cells and biproducts away from cells 
    May be easily modified to promote cell adhesion 
    Can be injected as a liquid that subsequently gels or crosslinks  
    Usually biocompatible 
 
Disadvantages 
    Can be hard to handle 
    Usually mechanically weak 
    May be difficult to load drugs and cells and then crosslink as a prefabricated scaffold
    May be difficult to sterilize 
Adapted from [46]. 
 
Table 1.3 Applications of hydrogels as tissue engineering scaffolds 
Scaffolding Application Hydrogel Material Reference
Liver Alginate [48] 
 Chitosan [49] 
   
Skin Collagen [14,15] 
 Gelatin-hyaluronic acid [50] 
 Polyethylene glycol [31] 
   
Blood vessel Collagen [10] 
   
Neural  Polyhydroxypropyl methacrylamide [30] 
 Agarose [26] 
 Chitosan-collagen [51] 
 Fibrin [29] 
   
Soft tissue augmentation Alginate [52] 
 Hyaluronic acid [53] 
   
Pancreatic islet encapsulation Alginate [7] 
 Polyethylene glycol [9] 
 Polyvinyl alcohol [8] 
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Table 1.4 Vertebrate biomaterials  
 Proteins Glycosaminoglycans 
Examples: Fibronectin 
Fibrin 
Elastin 
Collagen/Gelatin 
Keratin 
Hyaluronic acid 
Dermatan sulfate 
Chondroitin sulfate 
Keratan sulfate 
Heparin sulfate/Heparin 
 
Repeat unit: 
Bioactivity: 
Stability: 
Solubility: 
Immunogenicity:
Amino acids 
High 
Fair to poor 
Varies 
Possible 
Carbohydrates 
(Current area of research) 
Good 
High 
Generally low 
 
Natural polymers are derived from vertebrate and non-vertebrate sources, 
each of which has unique advantages and disadvantages. For example, vertebrate 
derived biomaterials (Table 1.4) are less likely to invoke an acute immune 
response, but are limited in supply or may carry pathogenic viruses (e.g., human 
immunodeficiency virus or HIV) or prions (e.g., bovine spongiform 
encephalopathy or Mad Cow Disease). Non-vertebrate natural polymers (e.g., the 
sea-weed derived polymers agarose and alginate) are available in a larger supply, 
but may provoke a strong immune response.  
 In our work, we chose to focus on hyaluronic acid (HA), a naturally 
derived glycosaminoglycan whose relatively simple sugar-like structure is nearly 
ubiquitous throughout all organisms. As a candidate biomaterial, HA presents a 
unique combination of advantages; specifically, HA is a naturally derived, 
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enzymatically degradable, non-immunogenic, non-adhesive, bioactive polymer 
that plays key roles in a variety of cellular processes (described in more detail 
below). A brief overview of HA and the HA-based hydrogel work presented in 
this dissertation follows. 
1.5 OVERVIEW OF DISSERTATION 
This dissertation is organized into six chapters. In Chapter 2, we give a 
detailed description of the foundation of our hydrogel biomaterial, HA. This 
unique biopolymer plays a vital role in embryonic development, extracellular 
matrix homeostasis, wound healing, and tissue regeneration. Biomaterials made 
from derivatized and crosslinked HA have received a great deal of attention in the 
bioengineering community and have been used in a wide variety of applications. 
HA has great potential for creative application in biomedical engineering as it is 
naturally derived, non-immunogenic, inherently bioactive, and has multiple sites 
for modification. This chapter reviews HA's natural structure and function, 
biomaterials made from derivatized and crosslinked HA as well as a number of 
clinical, surgical, and bioengineering applications of HA. 
In Chapter 3, we present the synthesis and characterization of our 
hydrogel scaffolding material, photocrosslinked glycidyl methacrylate-modified 
HA (GMHA). A range of hydrogel degradation rates was achieved as well as a 
corresponding, modest range of material properties. Increased amounts of 
conjugated methacrylate groups corresponded with increased crosslink densities 
and decreased degradation rates and yet had an insignificant effect on human 
aortic endothelial cell cytocompatibility and proliferation. Rat subcutaneous 
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implants of the GMHA hydrogels showed good biocompatibility, little 
inflammatory response, and similar levels of vascularization at the implant edge 
compared with those of fibrin positive controls. Through the work presented in 
this chapter, we concluded that these novel GMHA hydrogels were promising 
biomaterials suitable for further optimization. 
In Chapter 4, we describe studies that further tune the material and 
biological properties of the GMHA hydrogels for soft tissue engineering 
applications. We conjugated GMHA with acrylated forms of polyethylene glycol 
(PEG) and PEG-peptides to yield GMHA-PEG-peptide composite hydrogels. By 
varying the reactant concentrations, we created solid hydrogels with high peptide 
conjugation efficiencies, controllable peptide concentrations, and defined 
physicochemical properties. Furthermore, when modified with a peptide 
containing the adhesive peptide sequence RGD, the GMHA-PEG-peptide 
composites are able to support increased levels of human fibroblast adhesion 
compared to GMHA-PEG hydrogels alone. In summary, we demonstrated that the 
GMHA hydrogels could be modified to increase cellular adhesion while also 
maintaining the ability to fine-tune the hydrogel physicochemical properties. 
In Chapter 5, we present a series of studies that characterize the release of 
a model protein, bovine serum albumin, from GMHA and GMHA-polyethylene 
glycol (PEG) hydrogels. Though BSA was released rapidly, increased GMHA and 
PEG concentrations were correlated with decreased protein release rates. To 
lengthen the duration of release, poly(lactic-co-glycolic acid) (PLGA) 
microspheres containing encapsulated BSA were suspended within the hydrogel 
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matrix. We found that this approach was suitable for extending the duration of 
BSA release to several weeks. These initial studies indicated that the GMHA and 
GMHA-PEG hydrogels and hydrogel-microsphere composites are tunable 
systems for delivering stable proteins in soft tissue engineering applications.  
In Chapter 6, we summarize the results from our studies, draw 
conclusions, and recommend areas for future work. 
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Chapter 2: Hyaluronic Acid 
 Hyaluronic acid (HA, also called hyaluronan or hyaluronate), a high 
molecular weight glycosaminoglycan found in all mammals, is a unique and 
highly versatile biopolymer. HA plays a vital role in embryonic development, 
extracellular matrix homeostasis, wound healing, and tissue regeneration. 
Although it is clear that HA is critically involved in these processes, a detailed 
understanding of the exact mechanisms by which it influences cellular behavior is 
unresolved. Additional complications arise when considering that the behavior 
and cellular influence of HA is highly dependent on concentration and molecular 
weight. For all of these reasons, the biology and chemistry of HA is a current area 
of extensive scientific research. 
Biomaterials made from derivatized and crosslinked HA have received a 
great deal of attention in the bioengineering community and have been used in a 
wide variety of applications (e.g., orthopaedic, cardiovascular, ophthalmology, 
and dermatology, as well as general applications in tissue engineering, surgery, 
and drug delivery). HA has great potential for creative application in biomedical 
engineering because this unique polymer is naturally derived, non-immunogenic, 
inherently bioactive, and has multiple sites for modification. This chapter reviews 
HA's natural structure and function, biomaterials made from derivatized and 
crosslinked HA as well as a number of clinical, surgical, and bioengineering 
applications of HA. 
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2.1 THE NATURAL STRUCTURE AND FUNCTION OF HA 
2.1.1 Physicochemical and Structural Properties 
Hyaluronic acid, an extracellular matrix (ECM) component, is a high 
molecular weight glycosaminoglycan composed of disaccharide repeats of 
glucuronic acid and N-acetylglucosamine (Figure 2.1). This relatively simple 
structure is completely conserved through almost all mammals, suggesting that 
HA is a biomolecule of considerable importance [1]. In the body, HA occurs in 
the salt form, hyaluronate, and is found in high concentrations in several soft 
connective tissues, including skin, umbilical cord, synovial fluid, and vitreous 
humor. Notable amounts of HA are also found in lung, kidney, brain, and muscle 
tissues. In commercial production, HA is commonly extracted from rooster comb 
and human umbilical cord or manufactured in large quantities by bacterial 
fermentation [2].  
The cellular synthesis of HA is a unique and highly controlled process [3]. 
Most glycosaminoglycans are made in the cell's Golgi networks. HA, however, is 
synthesized at the plasma membrane and immediately extruded out of the cell and 
into the ECM. This process is carried out by a group of proteins called HA 
synthases, which are located in the cell membrane. For a review of HA synthases, 
see Lee & Spicer [3].  
 
 23
 
Figure 2.1 The structure of native HA.  
HA is a naturally derived polymer composed of disaccharide repeats of glucuronic acid 
and N-acetylglucosamine. The molecular weight of native HA is typically several 
million. Each disaccharide repeat of HA contains three possible modification sites: the 
hydroxyl, carboxyl, and acetamido groups. 
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HA's structure imparts unique physicochemical and biological properties 
that depend on molecular weight [2]. When extracted from tissues, HA is 
polydisperse in size, with an average molecular weight of several million. In 
physiological solution, HA conforms to a stiffened random coil with a contour 
length of about 2.5 µm for a 1 x 106 molecular weight chain of about 2650 
disaccharide repeats. Secondary hydrogen bonds form along the axis of HA, 
imparting stiffness and creating hydrophobic patches that allow the formation of 
ordered structures. HA solutions are shear-thinning; in other words, when shear 
rate is increased, the HA chains align in the direction of flow, resulting in a 
decreased solution viscosity. This shear thinning effect can be seen when 
delivering HA through a syringe.  
HA is a highly hydrophilic polymer. Each glucuronic acid unit contains 
one carboxyl group, giving rise to HA's polyanionic character at physiological 
pH. In the presence of water, HA molecules can expand in volume up to 1000 
times and form loose hydrated matrices [4]. Because of this property, HA is 
thought to play several roles in the ECM, including space filler, lubricant, and 
osmotic buffer [4]. By forming a hydrated polymer network, HA can act as a 
sieve, restricting the movement of pathogens, plasma proteins, and proteases [1,4]. 
In addition, HA's polyionic structure is able to scavenge free radicals, which 
mediates inflammation by imparting an antioxidant effect [1]. For a thorough 
review of HA's structural and physicochemical properties, see Lapcik, et al [2]. 
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2.1.2 Roles in the Extracellular Matrix and Interactions with Hyaladherins 
HA plays several important organizational roles in the ECM by binding 
with cells and other components through specific and non-specific interactions. 
For example, HA interacts with several proteoglycans (e.g., aggrecan, versican) 
through HA-binding motifs [2], and modulates the organization of fibrin, 
fibronectin, and collagen networks [5]. In addition to contributing to the 
homeostasis of ECM structure and hydration, HA is also involved in a number of 
more complex signaling events relating to cell migration, adhesion, and 
metastasis. Such processes are mediated through a group of proteins called 
hyaladherins. These proteins can be categorized into three types: those that are 
soluble, those that bind HA to other ECM molecules, and those that act as cellular 
receptors for HA.  
Two hyaladherins, CD44 and RHAMM (Receptor for HA-Mediated 
Mobility), have been extensively studied. CD44 has been implicated as the major 
cell surface receptor for HA, and is expressed on a variety of cell types (e.g., 
leukocytes, fibroblasts, epithelial cells, keratinocytes, and some endothelial cells) 
[6]. The CD44 receptor is associated with various cellular processes, including 
adhesion, migration, proliferation, and activation as well as HA degradation and 
uptake [1,4]. (See Figure 2.2 for a schematic of the signaling mechanisms 
associated with CD44.) In a number of cell types, the RHAMM hyaladherin has 
been found on the cell surface, as well as in the cytosol and nucleus [7]. RHAMM  
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Figure 2.2 Signaling pathways of the HA receptor CD44.  
The binding of HA and CD44 can result in signaling cascades that effect (a) the 
modification of cytoskeletal proteins, leading to changes in cell migration, and (b) the 
activation of gene transcription, resulting in changes in cell proliferation. Cytoskeletal 
assembly may be modified through signaling involving Rac and RhoA. The protein 
kinase C (PKC) and MAP kinase cascades may be involved in altering gene expression 
inside the nucleus. Figure adapted from [3]. 
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has been implicated in regulating cellular responses to growth factors and plays a 
role in cell migration, particularly for fibroblasts and smooth muscle cells [7,8]. 
For a comprehensive review of hyaladherins, see Toole [8]. 
2.1.3 HA's Complex Influence on Cell Migration 
As mentioned above, HA may influence cellular behavior not only 
through direct mechanisms (e.g., specific binding with cellular hyaladherins), but 
also by indirect means (through altering the physical properties of the ECM). 
HA's effect on cell migration is a remarkable illustration of this complexity. For 
instance, the binding of cellular hyaladherins to HA is involved in migration for a 
variety of cell types [5]. Yet, it is evident that HA may also indirectly aid cell 
migration by contributing to more open and hydrated spaces in the ECM or by 
otherwise remodeling the environment through interactions with collagen and 
fibrin [3]. Furthermore, as the main component of pericellular coats (matrices that 
are formed around migrating and proliferating cells), HA non-specifically 
facilitates the detachment of cells from the ECM [8]. In fact, as a highly 
hydrophilic polymer, HA is commonly referred to as a non-adhesive substrate 
(reviewed in [5]). Given such complexity, distinguishing between the effects of 
HA's biological activity and physicochemical properties is not straightforward.  
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2.1.4 HA Degradation 
In mammals, the enzymatic degradation of HA results from the action of 
three types of enzymes: hyaluronidase (hyase), β-D-glucuronidase, and β-N-
acetyl-hexosaminidase. Throughout the body, these enzymes are found in various 
forms, intracellularly and in serum. In general, hyase cleaves high molecular 
weight HA into smaller oligosaccharides while β-D-glucuronidase and β-N-acetyl-
hexosaminidase further degrade the oligosaccharide fragments by removing non-
reducing terminal sugars. Besides the degradation reaction, testicular hyase can 
catalyze the reverse reaction, transglycosylation. Therefore, HA is not simply 
degraded by this enzyme into disaccharide fragments. On the contrary, incubation 
of HA in a testicular hyase solution yields a mixture of fragment sizes, primarily 
made up of tetrasaccharides with smaller quantities of hexa-, octa-, and 
disaccharides [9]. The cell types primarily responsible for hyase synthesis are 
macrophages, fibroblasts, and endothelial cells; consequently, each of these cell 
types have been associated with HA degradation in the body [10]. In addition to 
enzymatic degradation, HA can also be degraded by reactive oxygen 
intermediates, a mechanism that has been implicated as a source of HA fragments 
at sites of inflammation [11]. For a review of other non-enzymatic means of HA 
degradation (e.g., degradation induced by free radicals, ultrasound, pH, and 
temperature treatments), see Lapcik, et al. [2]. 
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2.1.5 HA in Wound Repair and Angiogenesis  
High concentrations of HA can be found in many tissues undergoing 
remodeling, regeneration, and morphogenesis [8]. Furthermore, in the early stages 
of wound healing, a matrix composed largely of fibrin and HA is formed, which 
aids in fibroblast and endothelial cell migration into the injury site. This matrix 
also supports granulation tissue formation, particularly in fetal tissue, where HA 
has been implicated in aiding scar-free wound healing [1]. For this reason, 
exogenous HA has been investigated in wound healing applications and has been 
found to be effective even in challenging conditions such as chronic wounds [1].  
The exact role of HA in wound healing is very complicated. In a 
comprehensive review of HA and wound repair, Chen and Abatangelo suggest 
that HA plays a "multifaceted" role in each wound healing stage (i.e., 
inflammation, granulation tissue formation, reepithelization, and remodeling) [1]. 
For example, HA aids in launching the early stages of inflammation, initiating the 
wound healing response, and also moderates the later stages of this potentially 
damaging process. Furthermore, the granulation tissue that forms remains rich in 
HA, aiding cell migration, proliferation, and organization of the ECM.  
Perhaps one of the most interesting roles of HA in wound healing is the 
ability of HA oligosaccharides to promote angiogenesis [10]. Degradation 
products of 4-20 disaccharide units have been shown to stimulate in vivo capillary 
growth and induce in vitro endothelial proliferation, migration, and tube 
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formation. The complex nature of HA, however, is again demonstrated: although 
low molecular weight HA promotes angiogenesis, high molecular weight HA has 
been shown to inhibit new blood vessel growth.  Researchers have attempted to 
gain a better understanding of the direct and indirect effects of HA molecular 
weight on angiogenesis, but an exact understanding of this process remains to be 
elucidated. For a review of the role of HA in angiogenesis, see West and Fan [10]. 
2.1.6 The Role of HA in Pathological Processes 
Factors such as HA concentration and molecular weight have been 
correlated with the development of certain pathological conditions and can be 
used as diagnostic markers for disease. Increased serum concentrations of HA can 
be associated with the progression of certain inflammatory processes, such as 
rheumatoid arthritis, and have been used to evaluate the success of kidney and 
liver transplants [4]. Changes in the properties of HA have also been associated 
with certain vascular diseases, including atherosclerosis and restenosis [12]. 
Furthermore, high concentrations of HA have been linked to tumor growth and in 
some cases can be used as a negative predictor of cancer patient survival [12]. 
Presumably, a role of HA in cardiovascular disease and tumor growth is to 
increase the fluidity of the ECM, allowing increased cell proliferation and 
migration. In most cases, it is not clear whether the altered properties of HA 
directly cause disease or whether these changes are a symptom of the pathology; 
thus, a detailed understanding of HA's role in these conditions is incomplete [12].  
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2.2 DERIVATIZED AND CROSSLINKED HA BIOMATERIALS 
HA offers many unique advantages as a building block for biomedical 
devices. Specifically, HA is enzymatically degradable, naturally derived, and non-
immunogenic. Unlike proteins, which are easily denatured, HA is a carbohydrate 
polymer and can withstand demanding chemical modification procedures without 
losing its biological activity. Purified HA has found clinical uses in 
ophthalmology, osteoarthritis, and wound healing applications [2]. HA has many 
other potential applications, particularly as a biomaterial to deliver cells or 
proteins, but its use is limited because of its high water solubility and rapid 
degradation in the body. Thus, researchers have investigated methods to prolong 
the residence time of HA, using chemical modifications to yield materials with 
greater in vivo stability. Two main approaches for creating HA biomaterials have 
been utilized: derivatization and crosslinking (summarized in Figure 2.3). Both 
approaches are used to chemically modify one or more of HA's three available 
reactive groups (hydroxyl, carboxyl, and acetamido; Figure 2.1), while 
attempting to maintain biocompatibility and biological activity. This section 
provides an overview of several HA derivatization and crosslinking methods; 
however, this discussion is not comprehensive. For further information on 
modification strategies, including HA composites and blends, see references 
[2,13]. 
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Figure 2.3 Derivatized and crosslinked HA biomaterials.  
To tune HA's physicochemical properties for specific applications, HA has been modified 
in several ways. Un-crosslinked HA derivatives, including modifications based on (a) 
esterification [14], (b) carbodiimide-mediated reactions [15], and (c) sulfation [16,17] 
have been created. Crosslinked HA has also been produced using several crosslinking 
agents, including (d) diepoxies [18,19], (e) biscarbodiimides [20], (f) bifunctional amine 
crosslinkers [21], and (g) divinyl sulfone [22,23], as well as (h) photocrosslinking 
methods [24,25]. 
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2.2.1 HA Derivatives 
Many studies focus on three main types of HA derivatization strategies: 
esterification, carbodiimide-mediated modification, and sulfation (Figure 2.3a-c). 
These simple modification strategies can be used to create HA derivatives that are 
suitable for direct application or for subsequent crosslinking procedures. This 
section will describe uncrosslinked HA derivatives and Section 2.2.2 
("Crosslinked HA Biomaterials") will include a discussion of crosslinking 
methods for these materials.  
2.2.1.1 Ester Derivatives 
To create more hydrophobic forms of HA that have added rigidity and are 
less susceptible to enzymatic degradation, researchers have esterified HA's 
carboxyl groups [14]. The modification is carried out through an alkylation step of 
HA with an alkyl halide, yielding derivatives with 0-100% modifications of the 
available carboxyl groups. As the percent of HA esterification increases, these 
materials become more rigid and more hydrophobic. Increased hydrophobicity 
means that the HA derivatives are less soluble in water and less susceptible to 
enzymatic degradation. Fidia Advanced Biopolymers have created a range of HA 
esters, including ethyl esters (Hyaff-7; Figure 2.3a) and benzyl esters of HA 
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(Hyaff-11). Through a variety of processing steps, these HA esters can be shaped 
into fibers, membranes, sponges, and microspheres.   
2.2.1.2 Carbodiimide-Mediated Derivatives 
Reactions mediated by carbodiimides (e.g., EDC or 1-ethyl-3-(3'-
dimethylaminopropyl)carbodiimide) are a common means of covalently binding 
the carboxyl group of one bioactive molecule with an amine of another (e.g., 
reactions between amino acids during peptide synthesis). However, carbodiimide 
reactions are very sensitive to pH and often result in the formation of an 
unreactive intermediate, acylurea, from carboxyl groups. Therefore, depending on 
the reaction conditions, carbodiimide-mediated reactions on HA can result in very 
low coupling yields. (For excellent discussions of the challenges to carbodiimide-
mediated modification of HA, see references [15,20,21]). Pouyani and Prestwich 
gained a detailed understanding of these reactions, and as a result, chose 
hydrazide derivatization (Figure 2.3b) as a means of increasing the utility of 
carbodiimide in HA modifications [15]. Prestwich and co-workers have continued 
to develop a wide variety of HA-hydrazide derivatives for use as drug delivery 
devices, cellular probes, and HA-protein conjugates [13].  
2.2.1.3 Sulfated Derivatives 
To create a blood-compatible molecule that mimics heparin, researchers 
have modified HA with sulfate groups [16] (Figure 2.3c). The sulfation is 
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completed through a reaction of sulfur trioxide pyridine with HA's hydroxyl 
groups, yielding a range of sulfation from 1 to 4 sulfur groups incorporated per 
HA disaccharide [17]. This sulfation modification creates HA derivatives that are 
structurally and chemically similar to heparin [16,17]; cardiovascular applications 
of these materials are described in more detail below (see Section 2.3 
"Applications of HA Biomaterials"). 
2.2.2 Crosslinked HA Biomaterials 
As already mentioned, HA presents many inherent advantages as a 
candidate biomaterial. In addition to derivatization, crosslinking (Figure 2.3d-h) 
is another means of engineering HA's physicochemical properties. Depending on 
the crosslinking molecule and reaction chemistry, a wide variety of HA materials 
can be created, ranging from films with relatively low water content to highly 
swelling hydrogels. Most HA crosslinking methods fall into either of two general 
schemes: a one-step procedure consisting of the exposure of HA to a crosslinker, 
or a two-step procedure where a highly reactive HA derivative is first synthesized 
and then crosslinked in a subsequent reaction. Below is a brief listing of common 
HA crosslinking techniques; see references [2,13] for more detail. 
2.2.2.1 Diepoxy Crosslinking 
Almost 40 years ago, Laurent and co-workers created diepoxy crosslinked 
HA hydrogels using polyethylene glycol diglycidyl ether [18]. Others have 
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extended the diepoxy chemistry to other crosslinkers, including ethyleneglycol 
diglycidylether (a bifunctional crosslinker) and polyglycerol polyglycidylether (a 
trifunctional crosslinker) [19]. Interestingly, detailed studies of this chemistry 
have shown that at low pH, diepoxy compounds form ester linkages between 
carboxyl groups, while at high pH, they form ether linkages between hydroxyl 
groups [26] (Figure 2.3d). Thus, researchers have used diepoxyoctane to crosslink 
HA in a two-step double-crosslinking treatment: HA is reacted with 
diepoxyoctane at low pH, forming ester crosslinks, and then a second 
diepoxyoctane step is then carried out at high pH, forming ether crosslinks [26].   
2.2.2.2 Carbodiimide-Mediated Crosslinking 
As discussed above, carbodiimide-mediated reactions are commonly used 
for reactions between carboxylic acids and amines. These reactions, however, are 
sensitive to pH and readily form an unreactive acylurea from HA's carboxylates; 
therefore, the applications for which carbodiimides can be used with HA are 
somewhat limited. Fortunately, several researchers have found specific conditions 
under which carbodiimide-mediated reactions can allow HA crosslinking.  
The simplest of these methods uses solely carbodiimide to induce inter- 
and intramolecular crosslinks on HA [27]; in other words, these materials can be 
synthesized without the use of exogenous crosslinkers. To form crosslinks, the 
carbodiimide-mediated reaction is performed on films of at least 70 weight 
percent HA in acetone- or ethanol-water solutions. Similar reactions carried out 
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with HA in solution did not yield crosslinked materials, perhaps as a result of the 
formation of unreactive acylureas. Challenged by this tendency of carbodiimide-
mediated reactions to form unreactive acylureas on HA, Kuo, et al. created a 
biscarbodiimide crosslinking technique [20] (Figure 2.3e). Several 
biscarbodiimides were synthesized and covalently bound to HA through a 
mechanism similar to the carbodiimide-mediated creation of an acylurea, 
producing aromatic or aliphatic crosslinks between HA molecules. 
Finally, several efforts have utilized carbodiimides to mediate reactions 
between HA's carboxyl groups and the amines of bifunctional crosslinkers 
(Figure 2.3f). Bullpitt and Aeschlimann made use of reactions mediated with 
carbodiimide and 1-hydroxybenzotriazole (HOBt) to couple activated amines 
(pKa < 8.0; e.g., adipic dihydrazide) to HA's carboxyl groups; carbodiimide and 
N-hydroxysulfosuccinimide (sulfo-NHS) were used for coupling reactions 
between HA and simple primary amines (pKa > 9.0; e.g., 1,4-diaminobutane 
dihydrochloride) [21]. Similarly, Vercryusse and co-workers have synthesized a 
wide variety of polyvalent hydrazide crosslinkers (2-6 hydrazides per crosslinker) 
for use in carbodiimide-mediated crosslinking reactions [28].  
2.2.2.3 Aldehyde Crosslinking  
Formaldehyde and glutaraldehyde have long been used to crosslink 
proteins for tissue preservation. Formaldehyde is used to create Biomatrix's 
Hylan-A, a water-soluble form of crosslinked HA that is more viscous and elastic 
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than native HA [22]. Glutaraldehyde has been used to crosslink HA to yield 
materials with high resistance towards degradation. Tomihata and Ikade used 
glutaraldehyde in acidic acetone-water solutions to create crosslinked HA films of 
low water content [29]. Hu, et al. compared glutaraldehyde and carbodiimide-
mediated reactions and found that glutaraldehyde yielded more highly crosslinked 
materials suitable for use as three-dimensional tissue scaffolds [30].  
2.2.2.4 Divinyl Sulfone Crosslinking  
Insoluble HA hydrogels can be formed by crosslinking HA with divinyl 
sulfone (Figure 2.3g), yielding materials such as Biomatrix's Hylan-B gel 
[22,23]. At high pH, divinyl sulfone creates sulphonyl-bis-ethyl crosslinks 
between HA's hydroxyl groups. Depending on the reaction conditions, materials 
ranging from soft gels to firm solids (e.g., membranes and tubes) can be formed. 
Compared to native HA, Hylan-B has an extended residence time in vivo, 
particularly in sites where low mechanical force is imposed on the implant.  
2.2.2.5 Photocrosslinking  
While the crosslinking methods discussed above yield a wide variety of 
stabilized materials, most of these techniques proceed under physiologically 
incompatible conditions. Furthermore, many of these methods crosslink 
immediately upon mixing of the HA with the crosslinker. Because HA forms 
highly viscous solutions, it is often difficult to obtain homogenous materials in 
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this manner. Photocrosslinking, however, is a method that only reacts upon 
exposure to the appropriate wavelength of light; therefore, the reactants can be 
thoroughly mixed before crosslinking is initiated [31]. Furthermore, 
photocrosslinking methods are capable of proceeding under physiological 
conditions without detrimental effects to copolymerized bioactive molecules or 
encapsulated cells. To this end, HA has been modified with several 
photocrosslinkable groups, including cinnamoyl, coumarin, and thymine [32]; 
methacrylic anhydride [24]; glycidyl methacrylate [25]; and styrene [33]. (See 
Figure 2.3h for a general schematic of photocrosslinking methacrylated HA 
derivatives; Chapters 3-5 detail several studies focusing on the development of 
photocrosslinkable glycidyl methacrylate-modified HA hydrogels.) Finally, 
sulfated HA has been modified with 4-azidoaniline, yielding an HA derivative 
suitable for patterning features as small as 100 µm [34], which may be useful for 
directing cell growth or adhesion in new biomaterials.  
2.3 APPLICATIONS OF HA BIOMATERIALS 
HA's intrinsic physicochemical and biological properties suggest that this 
distinctive polymer is suitable for application in clinical therapies, diagnostics, 
tissue engineering, and drug delivery. For comprehensive reviews of medical 
applications of HA, see references [2,13]. Table 2.1 provides a list of HA products 
currently approved by the FDA for clinical use. 
 40
Table 2.1 FDA approved HA products. 
Application Tradename Company 
Osteoarthritis Hyalgan Fidia 
 Synvisc Biomatrix/Genzyme 
 Supartz Seikagaku 
 Hylashield Biomatrix 
   
Ophthalmology Healon Pharmacia 
 Amvisc Bausch & Lomb 
 Coease, Shellgel, Staarvisc Anika Therapeutics 
 Amo Vitrax, Vitrax Allergan/Medtronic 
 Provisc, Viscoat Alcon Laboratories 
   
Wound healing Bionect Fidia 
 Ialuset IBSA 
   
Postsurgical adhesions Adcon Gliatech 
 Intergel LifeCore Biomedical 
 Seprafilm Genzyme 
   
Surgical scaffolding Hyalomatrix Fidia 
 Hylasine Biomatrix 
   
Gastrourology Deflux Q-Med 
    Adapted from [2,13,35] 
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2.3.1 Orthopaedic Applications 
Native HA plays a vital role in the development of cartilage, the 
maintenance of the synovial fluid, and the regeneration of tendons [8]. High 
concentrations of HA can be found in the ECM of all adult joint tissues, including 
the synovial fluid and the outer layer of cartilage [36]. In part because of its 
viscoelastic nature and ability to form highly hydrated matrices, HA acts in the 
joint as a lubricant and a shock absorber [37]. In diseases such as osteoarthritis, 
the concentration and molecular weight of the HA naturally present in the joint 
are decreased, contributing to stiffness and pain. Viscosupplementation treatments 
aim to treat these conditions, and to this end, a variety of HA materials have been 
successfully applied as clinical therapies [36,37].  
Researchers have also investigated modified HA as a cell delivery scaffold 
for cartilage and bone tissue engineering. Esterified HA (Hyaff, Fidia Advanced 
Biopolymers) supports the growth of chondrocytes [38] and the differentiation of 
bone marrow-derived mesenchymal progenitor cells into chondrocytes and 
osteoblasts [39]. In fact, when compared to one well-characterized delivery 
vehicle (porous calcium phosphate ceramic), Hyaff materials allowed greater 
amounts of bone and cartilage to be formed in vivo (as determined from the image 
analysis of stained tissue sections) [39]. 
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2.3.2 Anti-Adhesion Applications 
As HA is highly hydrophilic, it is a polymer that is well suited for 
applications requiring minimal cellular adhesion. Postoperative adhesions, which 
form between adjacent tissue layers following surgery, impede wound healing and 
often require additional surgical procedures to repair successfully. Barriers made 
from crosslinked HA have been effectively used to prevent such adhesions from 
forming [32].  Furthermore, the adhesion of bacteria onto biomaterials can induce 
infections and great risk to the patient; with this in mind, esterified HA has also 
been used to prevent bacterial adhesion to dental implants, intraocular lenses, and 
catheters [40].  
2.3.3 Cardiovascular Applications 
HA has also proven to be effective for increasing the blood compatibilities 
of cardiovascular implants such as vascular grafts and stents. For example, 
biomaterial surfaces treated with crosslinked HA have been associated with 
reduced platelet adhesion and thrombus formation [22,34,41]. Furthermore, 
sulfated HA derivatives can act as heparin mimics [16,17]; in fact, HA derivatives 
with higher degrees of sulfation are associated with increased abilities to prevent 
blood coagulation (as measured by longer times required for whole blood 
clotting) [17]. 
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Crosslinked HA is also a promising biomaterial for cardiac tissue 
engineering. In the embryo, HA is required for the normal development of the 
valves and chambers within the heart [42]. Building upon this information, studies 
by Masters and Anseth have indicated that photopolymerized HA hydrogels are 
suitable materials for constructing tissue engineered heart valves (K.S. Masters 
and K.S. Anseth, Department of Chemical Engineering, The University of 
Colorado at Boulder, 2003, personal communication). Valvular interstitial cells, 
which are the primary cell type found in heart valves, were shown to adhere to 
and proliferate upon the HA hydrogels. Furthermore, the hyaladherins CD44 and 
RHAMM are present on the valvular interstitial cells and these receptors were 
thought to be involved in promoting cellular proliferation in response to degraded 
HA hydrogel fragments.  
2.3.4 Ophthamology 
HA, a natural component of the vitreous humor of the eye, has been used 
for many successful applications in ophthalmologic surgery [2]. In part because it 
forms viscoelastic and highly hydrated matrices, HA is particularly useful as a 
space-filling matrix in the eye; thus, intraocular injection of HA during surgery is 
used to maintain the shape of the anterior chamber. Furthermore, HA solutions 
also serve as a viscosity-enhancing component of eye drops and an adjuvant to 
eye tissue repair. 
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Figure 2.4 Crosslinked HA hydrogel films to assist wound healing.  
Full-thickness wounds were created in the skin of Balb/c mice and (a) treated with a 
crosslinked HA hydrogel film (adipic dihydrazide modified HA that was crosslinked with 
polyethylene glycol dialdehyde) and covered with a wound dressing (Tegaderm, a thin 
polyurethane membrane dressing that is impermeable to microorganisms, 3M Health 
Care, St. Paul, MN), or (b) covered with the wound dressing alone. After 10 days, the HA 
films were completely degraded and 4 out of 6 of the HA treated wounds were associated 
with the formation of an epithelial layer and a collagen-rich dermal layer. The tissues 
treated with the wound dressing alone were less consistent and had reduced re-
epithelialization. Tissue extracted from an area peripheral to the wound is shown in (c) as 
a normal tissue control. The sections are stained with Masson's Trichrome. D = dermis, E 
= epidermis, M = muscle. Scale bar = 100 µm. Images reprinted from [43]. 
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2.3.5 Dermatology and Wound Healing Applications 
HA is naturally present in high concentrations in the skin and soft 
connective tissues. Therefore, HA is an appropriate choice for a matrix to support 
dermal regeneration and augmentation. For example, Prestwich and co-workers 
found that crosslinked HA hydrogel films accelerate the healing of full-thickness 
wounds (Figure 2.4), presumably by providing a highly hydrated and non-
immunogenic environment that is conducive to tissue repair [43]. Hyaff scaffolds 
cultured in vitro with keratinocytes and fibroblasts have been used to create 
materials similar to skin, including two distinct epidermal and dermal-like tissue 
layers [38]. Moreover, as a result of its ability to form hydrated, expanded 
matrices, HA has also been successfully used in cosmetic applications such as soft 
tissue augmentation [45].   
2.3.6 Neural and Glial Applications 
HA treatments have also been associated with improved peripheral nerve 
regeneration. Injections of unmodified HA into a nerve guide have been 
associated with increased levels of physiological and functional regeneration [46]. 
Furthermore, when strands of crosslinked HA are coated with polylysine, 
Schwann cells are able to attach and proliferate on these materials [30]. It is 
possible that the presence of HA enables increased glial cell migration, more 
rapid neurite outgrowth or a more easily remodeled ECM between the nerve 
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stumps. However, the exact mechanism by which HA may aid this process is not 
well understood.  
2.3.7 General Tissue Engineering and Surgical Applications 
HA's unique biological properties have inspired the development of a 
variety of novel therapies for general surgical applications. For example, our 
laboratory has previously used HA as a dopant during the synthesis of polypyrrole 
[44], an electrically conductive polymer that alone can promote repair in a variety 
of systems. When compared to polypyrrole films without HA, composite films of 
HA and polypyrrole were associated with higher levels of vascularization in 
subcutaneous implants (Figure 2.5). Therefore, HA-polypyrrole materials could 
be suitable for tissue engineering applications that may benefit from electrical 
stimulation and enhanced angiogenesis. Other researchers have also utilized HA's 
antioxidant properties to assist in the prevention of inflammation. In vitro studies 
have indicated that several materials, including unmodified HA, Hyaff, and a 
steroid-ester of HA, possess antioxidant activities [47,48]. Such materials could 
aid in healing conditions such as chronic wounds and rheumatoid arthritis.  
2.3.8 Drug Delivery 
Because of its biocompatibility, biodegradability, and readily modified 
chemical structure, HA has been extensively investigated in drug delivery 
applications. A variety of commercially available preparations of HA derivatives 
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and crosslinked HA materials have been developed for drug delivery; these 
materials are created in forms such as films, microspheres, liposomes, fibers, and 
hydrogels. For excellent reviews on applications of HA in drug delivery, see 
references [2,13]. 
2.4 CONCLUSIONS AND FUTURE DIRECTIONS 
Through multidisciplinary discoveries about the structure, properties, 
biological activity, and chemical modification of this unique polymer, HA has 
found success in an extraordinarily broad range of biomedical applications. Future 
clinical therapies of HA-derived materials critically rely on a more detailed 
understanding of the effects of HA molecular weight and concentration and how 
this biomolecule specifically interacts with cells and ECM components in the 
body. Future directions of these materials will require finely tuned and 
controllable interactions between HA and its environment. Work in these areas 
are underway; for example, adhesive peptide sequences have been covalently 
bound to HA materials [49]. Also, environmentally responsive materials have 
been synthesized from HA. These materials can be created to swell or degrade in 
response to inflammation [19], electrical stimulation [50], and heat [51]. For an 
excellent online resource regarding the biology, modification chemistries, and 
various applications of HA, see the Glycoforum website [52].  
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Figure 2.5 Polypyrrole-HA composite films for tissue engineering applications. 
(a) Polypyrrole-HA and (b) polypyrrole-polystyrene sulfonate (negative control) films 
were implanted subcutaneously in rats for two weeks. The tissue sections were stained 
with hematoxylin and eosin. The heavy black lines in both images are the films. Blood 
vessels are denoted by arrows. The polypyrrole-HA films were associated with roughly a 
two-fold enhancement in blood vessel area compared the polypyrrole-polystyrene 
sulfonate films. Scale bar = 100 µm. Images reprinted from [44]. 
 
 
a 
 
 
 
 
 
 
 
b 
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Chapter 3: Glycidyl Methacrylate-Hyaluronic Acid Hydrogels 
Ideally, rationally designed tissue engineering scaffolds should promote 
natural wound healing and regeneration. Therefore, we sought to synthesize a 
biomimetic hydrogel specifically designed to promote tissue repair and chose 
hyaluronic acid (HA; also called hyaluronan) as the material from which to start.  
We prepared a range of glycidyl methacrylate-HA (GMHA) conjugates, 
which were subsequently photopolymerized to form crosslinked GMHA 
hydrogels. A range of hydrogel degradation rates was achieved as well as a 
corresponding, modest range of material properties (e.g., swelling, mesh size). 
Increased numbers of conjugated methacrylate groups corresponded with 
increased crosslink densities and decreased degradation rates and yet had an 
insignificant effect on human aortic endothelial cell cytocompatibility and 
proliferation. Rat subcutaneous implants of the GMHA hydrogels showed good 
biocompatibility, little inflammatory response, and similar levels of 
vascularization at the implant edge compared with those of fibrin positive 
controls. Therefore, these novel GMHA hydrogels are suitable for modification 
with adhesive peptide sequences (e.g., RGD) and use in a variety of soft tissue 
engineering applications. 
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3.1 INTRODUCTION 
As discussed in Chapter 1, future biomaterials applications will rely on 
scaffolds and drug delivery devices that interact with living systems in a 
specifically designed manner. A number of recent review articles have stated that 
such materials will be "biomaterials that heal": that is, biomimetic materials that 
are designed to promote natural healing and regeneration [1-3]. Therefore, several 
criteria are required: 1) the design of the biomaterial must incorporate the natural 
wound healing biology; 2) nonspecific adsorption of proteins should be inhibited; 
and 3) the biomaterial surface should present biomimetic molecules like those that 
are present in a wound [2].  
 To this end, numerous researchers have created and tested in vivo 
scaffolds composed of polysaccharides [4-7], proteins [8,9] and synthetic 
molecules [10-12]. These materials have found various degrees of success, but 
few have met all the requirements described above for "healable biomaterials." 
Additionally, candidate materials should be nonimmunogenic and have controlled 
biodegradability, biocompatible polymerization chemistry, and versatile 
modification strategies (e.g., multiple different reaction sites) [2,3,13]. One 
naturally derived polymer, hyaluronic acid (HA, Figure 3.1), inherently meets 
many of the above requirements and when crosslinked via photopolymerization, 
has the potential to provide an ideal wound healing scaffold.  
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As mentioned in Chapter 2, HA is a naturally derived, nonimmunogenic, 
nonadhesive glycosaminoglycan that plays a prominent role in various wound 
healing processes, as it is inherently angiogenic when degraded to small 
fragments [14]. HA promotes early inflammation, which is critical for initiating 
wound healing, but then moderates later stages of this process, allowing matrix 
stabilization and reduction of long-term inflammation [14] (Table 3.1). 
Furthermore, immunohistochemical analysis reveals that the environments around 
the migrating and proliferating fetal cells and adult tissues involved in 
regeneration and wound healing are enriched with HA [14]. As a mimic of the 
embryonic environment, exogenous HA supplementation promotes faster and 
more extensive regeneration in adult injuries [14]. This cumulative evidence 
suggests that HA is an ideal candidate material for modulating wound healing.  
Several physiochemical aspects of HA are advantageous for biomaterial 
fabrication and application. For example, HA can be easily and controllably 
produced in large quantities through microbial fermentation, enabling the scale-up 
of HA-derived products [15] and avoiding the risk of animal-derived pathogens. 
Nascent HA is highly hydrophilic and thus inherently nonadhesive to proteins and 
cells [16], valuable properties for preventing scar tissue [17] and capsule 
formation [2].  
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Figure 3.1 Native and crosslinked HA.  
(a) HA is a polymer composed of disaccharide repeats of glucuronic acid and 
acetylglucosamine and has a molecular weight in the millions (n ≅ 5000). (b) Native HA 
(shown schematically) is quickly degraded in vivo by the enzyme hyaluronidase. (c) 
Crosslinking the HA chains forms an insoluble hydrogel matrix that is more resistant to 
enzymatic degradation. (d) Glycidyl methacrylate (GM), a source of photopolymerizable 
methacrylate, reacts covalently with HA to form GMHA conjugates. 
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Table 3.1 HA and the wound healing process 
Wound Healing 
Phase 
Contributing Role of HA 
Inflammation - Activation of macrophages and neutrophils  
 - Production of proinflammatory cytokines 
 - Moderation of inflammation through free radical  
scavenging, antioxidant properties, inhibition of 
inflammatory proteinases 
  
Granulation - Cellular differentiation, proliferation, and migration 
 - Angiogenesis 
  
Remodeling - Reduced scar formation 
 
Adapted from Chen and Abatangelo [14] 
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HA is enzymatically degraded by hyaluronidase and is completely 
resorbable through multiple metabolic pathways [18]. Although HA is quickly 
broken down in vivo, crosslinking individual HA polymer chains together 
decreases their degradation rates (Figure 3.1b,c). Many strategies exist for 
crosslinking HA [18], and of these, we chose photopolymerization—a technique 
that provides advantages such as increased spatial and temporal control over 
crosslinking and biocompatibility with in situ polymerization [13,19]. 
The goal of the work presented in this chapter was to create unique HA 
hydrogels designed to support wound healing. We characterized several hydrogel 
physiochemical parameters, including swelling ratio, stiffness, and in vitro 
enzymatic degradation. Furthermore, human aortic endothelial cell studies and rat 
subcutaneous implants were used to analyze the possible deleterious effects of the 
synthesis and polymerization reactions. We synthesized GMHA hydrogels in a 
controlled manner to yield biocompatible materials that generally retain the 
desirable wound healing properties of nascent HA. 
3.2 MATERIALS AND METHODS 
3.2.1 Synthesis and Crosslinking of GMHA Conjugates 
We first added photopolymerizable methacrylate groups to HA to yield 
glycidyl methacrylate-HA (GMHA) conjugates (for a detailed protocol, see 
Appendix A.1). Briefly, we prepared a series of GMHA polymers by treating a 
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1% w/v solution of fermentation-derived HA (~2 x 106 molecular weight, Clear 
Solutions Biotech, Inc., Stony Brook, NY) in distilled water with a 6-, 10-, or 20-
fold molar excess of glycidyl methacrylate (GM; Figure 3.1d) in the presence of 
excess triethylamine and tetrabutyl ammonium bromide overnight at room 
temperature, followed by a 1-h incubation at 60°C. For example, GMHA 
synthesized with a 6-fold molar excess GM was made as follows: 1.0 g HA was 
dissolved in 100 ml distilled water; 2.2 ml triethylamine, 2.2 ml GM, and 2.2 g 
tetrabutyl ammonium bromide were added separately and thoroughly mixed 
before the next component was added. After the reaction, the solution was 
precipitated in acetone (20 times the volume of the reaction solution) and 
dissolved in distilled water twice to remove excess reactants. The GMHA solution 
was lyophilized and stored desiccated at 4°C. 1H-NMR spectroscopy was used to 
verify the methacrylation reaction on HA. GMHA conjugates were dissolved in 
D2O and the spectra were recorded using a Varian Inova-500 spectrophotometer. 
Next we synthesized the photocrosslinked hydrogels by exposing GMHA 
(0.5-2.0% w/v in phosphate-buffered saline) to UV light (365 nm, ~22 mW/cm2, 
0.5-5 minutes exposure) in the presence of the photoinitiator Irgacure 2959 (0.01-
3% w/v, Ciba Specialty Chemicals, Basel, Switzerland) and N-vinyl pyrrolidinone 
(0.03-12% v/v).  
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3.2.2 Swelling Experiments and Flory-Rehner Calculations 
To analyze the GMHA hydrogel structure (e.g., relative degrees of 
crosslinking), we performed a number of swelling experiments (for a detailed 
protocol, see Appendix A.2). The hydrogel swelling ratio based on mass (QM) 
was calculated by dividing the gel mass after swelling (Ms) by the dry gel mass 
(Md). A Perkin-Elmer (Wellesley, MA) thermogravimetric analyzer (TGA) was 
used to measure Ms and Md. The hydrogels were preswollen in phosphate-
buffered saline (PBS) overnight, cut into small pieces (10-20 mg), and placed in 
the TGA weighing pan. The initial swollen mass was recorded as Ms, and the 
sample was heated slowly to 90-100°C or until a constant mass was achieved. The 
final mass obtained was recorded as Md.  
 We then used Flory-Rehner calculations to determine the crosslink density 
and mesh size of the GMHA hydrogels. The average molecular weight between 
crosslinks, cM , was calculated using a simplification of the Flory-Rehner 
equation [20,21]: 

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
 χ−υ≅
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Q
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5
v       (3.1) 
where Qv is the volumetric swelling ratio, υ  is the specific volume of the dry 
polymer, cM is the average molecular weight between crosslinks, V1 is the molar 
volume of the solvent (18 mol/cm3 for water), and χ is the Flory polymer-solvent 
interaction parameter. 
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 Qv was determined from the degree of mass swelling, QM [22]: 
)1Q(1Q M
s
p
v −ρ
ρ
+=       (3.2) 
where ρp is the density of the dry polymer (1.229 g/cm3) and ρs is the density of 
the solvent (1 g/cm3 for water). QM and ρp values were determined experimentally 
and used to calculate Qv.  
The value of χ for HA was estimated to be 0.473, based on several 
assumptions. First, it was assumed that χ for HA is comparable to that for 
dextran, a well-studied polysaccharide, because HA and dextran have similar 
chemical structures. In addition, χ estimates for HA that were based on an 
analysis similar to those published by Gekko [23,24] gave values within 2% of the 
value of χ for dextran. Finally, differences between soluble, unmodified 
polysaccharides and crosslinked polymers were assumed to be negligible. 
The effective crosslink density, νe, was calculated as follows [25]: 
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The swollen hydrogel mesh size, ξ, was determined with the following 
equation [26,27]:  
 2o3
1
v rQ=ξ       (3.4)  
 65
where 2or  is the root-mean square distance between crosslinks and depends on 
the molecular weight between crosslinks. For HA, the following root-mean-
square end-to-end distance value was previously reported [28]:  
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      (3.5) 
where n is the number of disaccharide repeat units for HA with a given molecular 
weight. For HA with the molecular weight (Mn) 2 x 106, n is 5305, and therefore,  
 (nm)     M0.1748r n
2
0 =      (3.6) 
A combination of (3.4) and (3.6) and a substitution of cM  for Mn gives 
 (nm)   QM1748.0 3
1
vc=ξ     (3.7) 
Because approximations were made in the Flory-Rehner calculations, the values 
determined (e.g., cM , νe, ξ) were considered approximations. However, these 
values were useful for making order-of-magnitude comparisons of the GMHA 
chemistries for biologically relevant features, such as mesh size.  
3.2.3 Rheological Experiments 
To further characterize the crosslinking of the GMHA hydrogels, we 
performed rheological oscillatory shear stress experiments. Degree of crosslinking 
relates to gel stiffness, which is represented by the experimentally determined 
complex modulus (G*). A Paar Physica (Ashland, VA) MRC 300 modular 
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compact rheometer was used in the parallel plate geometry, with a 25-mm plate 
and a gap size of 1 mm. Constant values of deformation, 0.1-10 mrad, were 
maintained throughout each frequency sweep of 1-10 Hz. G* was obtained at 3 
Hz oscillation and 1 mrad deformation for each sample and was used to compare 
the relative mechanical stiffness of the hydrogels. 
3.2.4 In Vitro Degradation By Hyaluronidase 
In vitro enzymatic degradation of the hydrogels was measured as a 
function of time by incubating the gels in hyaluronidase and monitoring the mass 
of the hydrogel (for a detailed protocol, see Appendix A.3). First, the gels were 
synthesized in 8-mm diameter, 2-mm deep rubber perfusion chamber molds 
(Sigma-Aldrich, St. Louis, MO). The hydrogels were carefully transferred to 24-
well plates with Teflon-coated cover glass forceps and were soaked in citrate 
buffer (0.15 M NaCl, 0.15 M Na2HPO4-7H20, 0.03 M citric acid, pH 5.3) 
overnight to reach swelling equilibrium. The gels were removed from the citrate 
buffer, excess liquid was blotted from the surface with filter paper, and the gel 
masses were determined. Bovine testicular hyaluronidase (Sigma-Aldrich) in 
citrate buffer (0.5 ml of 5, 50, or 500 U/ml) was added to each gel and then 
incubated for various times at 37°C with mild mixing on a platform shaker. Every 
1-2 h, the solution was removed, the gels were blotted, and the masses were 
carefully determined. The gels were then returned to the 24-well plate and 
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replenished with fresh hyaluronidase solution for the remainder of the degradation 
study. Gels with little crosslinking (and therefore those that could be easily 
damaged) were used only for a single time point.  Crosslinked GMHA hydrogels 
in citrate buffer were used as a negative control. 
3.2.5 HAEC Cytocompatibility Studies 
 We investigated the cytocompatibility of human aortic endothelial cells 
(HAECs) with crosslinked and uncrosslinked 11% methacrylated GMHA 
hydrogels using an indirect contact method adapted from Trudel and Massia [29] 
(for a detailed protocol, see Appendix A.4). Transwell inserts (Costar; 6.5 mm, 
0.4-µm pore size polyester membrane filter, Corning Costar Corp., Acton, MA) 
were used to hold the hydrogel in indirect contact (1 mm separation distance) with 
the HAECs, which were seeded in the wells of the 24-well plates. The HAECs 
(Clonetics, Walkersville, MD) were obtained at passage 3, used at passage 6-8, 
and maintained in Clonetics’ endothelial growth media-2: modified MCDB-131 
supplemented with growth factors (EGM-2). All HA and GMHA solutions were 
sterilized with a syringe filter (0.8/0.2 µm Supor Acrodisc PF (prefilter) syringe 
filter, Pall Gelman, Ann Arbor, MI). 
 First, we compared the cytocompatibilities of HA and uncrosslinked 
GMHA. HAECs were seeded in a 24-well plate, 6250 cells in 1 ml EGM-2 per 
well. After the cells had adhered, the wells were dosed with 0.1 ml of 1% GMHA 
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in PBS, 1% HA in PBS or PBS alone (EGM-2 positive control). The final 
dilutions were approximately 0.1% GMHA and 0.1% HA. After 24 h, the cell 
viabilities were measured using the CellTiter 96 non-radioactive cell proliferation 
assay (Promega, Madison, WI) according to the manufacturer's instructions. The 
CellTiter assay is a colorimetric method for measuring the number of viable cells; 
therefore, the absorbance of the colored product is proportional to the number of 
living cells. At least three wells were treated, and the experiment was performed 
twice. Cell numbers were normalized versus the EGM-2 control.  
 Next, the cytocompatibility effects of crosslinked GMHA hydrogels were 
examined. A 0.1 ml GMHA solution with 1% Irgacure 2959 and 0.3% N-vinyl 
pyrrolidinone was dispensed in each Transwell insert and exposed to UV light for 
1 min in a laminar flow hood. The gels were washed in EGM-2 (twice for 1 min 
and once for 5 min). Solutions of 1% GMHA with either 1% Irgacure 2959 or 
0.3% N-vinyl pyrrolidinone were also tested to examine the effects of each 
component alone. After dilution by the medium, the final dilutions were 0.1% 
GMHA (crosslinked or uncrosslinked), 0.1% Irgacure 2959, and 0.03% N-vinyl 
pyrrolidinone. Finally, the experiment was repeated with crosslinked GMHA 
hydrogels made with 10-fold lower concentrations of Irgacure 2959 and N-vinyl 
pyrrolidinone.   
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3.2.6 HAEC Proliferation Response to Degraded GMHA 
 Degraded HA promotes angiogenesis and endothelial cell proliferation 
[30]. However, this response can be altered by the addition of methacrylate 
groups to HA. Therefore, the proliferation response of HAECs was determined in 
the presence of degraded HA and degraded GMHA in 96-well plates (for a 
detailed protocol, see Appendix A.5). HA and GMHA (5, 7, 11% methacrylation) 
were degraded in 50 U/ml hyaluronidase in citrate buffer for 4 h at 37°C, and then 
the hyaluronidase was inactivated by incubation at 56°C for 30 min. The HA and 
GMHA fragments were diluted to 1.5 µg/ml (this concentration of purified HA 
fragments increases the proliferation of bovine microvascular endothelial cells 
[30]) in "starvation medium" (Clonetics’ endothelial basal media-2: modified 
MCDB-131 (EBM-2) with 1% heat-inactivated fetal bovine serum at pH 7.4).  
The HAECs were seeded at 10,000 cells per well in EGM-2 and allowed 
to adhere for 2 h. The EGM-2 was removed and the cells were incubated 
overnight in the starvation medium. Next, the medium was replaced with the HA 
or GMHA fragment solutions and incubated for 48 h. Additional wells were also 
treated with EGM-2 (the positive control) or the starvation medium with heat-
inactivated hyaluronidase (the negative control). The cell viabilities were 
determined using Promega’s CellTiter 96 non-radioactive cell proliferation assay. 
At least three wells were exposed to each treatment, and the experiment was 
performed three times.  
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Figure 3.2 TEC subcutaneous implants in rats.  
(a) TEC devices filled with the gels were implanted into subcutaneous locations in rats. 
(b) The TEC devices allow the gels to be localized and easily identified upon 
explantation. (c) Implantation locations for assessment of in vivo degradation rate.  
 
 
 71
3.2.7 GMHA Implants  
In collaboration with Dr. Charles Patrick, Jr. at The University of Texas 
M.D. Anderson Cancer Research Center (Houston, TX), we investigated the 
endothelial cell response to the GMHA hydrogels in subcutaneous implants in 
rats. We used "tissue engineered construct" (TEC, Figure 3.2a,b) devices to 
identify the location of the implant and to simplify the harvesting procedure 
[31,32]. Each TEC is 8.5 mm in diameter, 4.0 mm deep, has a sewing cuff that is 
5-7 mm wide, and is made from polypropylene film using a custom-made heated 
die press mold.  
Sterile GMHA solutions (7% methacrylation, 1% GMHA, 1% Irgacure 
2959, 0.3% N-vinyl pyrrolidinone in PBS; 0.3 ml per TEC) were dispensed in the 
TECs and exposed to UV light for 1 min. Human fibrin (Tisseel fibrin sealant, 
Baxter Healthcare Corp., Glendale, CA) was used as a positive control for 
vascularization [33]. Agarose (1.5% w/v in water; Sigma-Aldrich) was used as a 
negative control. Four ~250 g male Lewis rats (Harlan, Indianapolis, IN) were 
anesthetized (0.1 ml/g intramuscular injection of 100 mg/ml ketamine, 20 mg/ml 
xylazine, 0.4 mg/ml atropine), shaved, and two 2.5-cm incisions were made in the 
skin along the spine (see Figure 3.2c). Blunt dissection was used to form a pocket 
between the skin and muscle, and the muscle surface was cleared of fascia. The 
TECs were sutured to the muscle using 5.0 Prolene polypropylene sutures 
(Ethicon, Inc., Somerville, NJ), with the hydrogel in direct contact with the 
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muscle surface (Figure 3.2b). After implantating four TECs per rat (one fibrin 
positive control, one agarose negative control, and two HA gels), the skin was 
closed with 9-mm surgical staples.  
At 2 weeks, the TECs and enclosed tissue were explanted, snap-frozen in 
Tissue-Tek optimal cutting temperature (OCT) compound (Sakura Finetek USA, 
Torrance, CA), and cryosectioned perpendicular to the muscle surface (6-µm 
sections). The sections were stained with the CD31 endothelial cell marker and 
counterstained with Gills #3 hematoxylin (Sigma-Aldrich), according to the 
methods described in [31] (for a detailed protocol, see Appendix A.6). Briefly, 
the sections were stained with a mouse antirat CD31 primary antibody (Serotec, 
Raleigh, NC) and a goat antimouse IgG secondary antibody conjugated with 
horseradish peroxidase (Serotec). CD31-positive cells were visualized using the 
substrate 3,3-diaminobenzidinetetrahydrochloride (DAB; Research Genetics, 
Huntsville, AL).  
The sections were imaged under brightfield using an Olympus IX-70 
inverted microscope (Melville, NY). Images were captured with a Hamamatsu C-
5810 color CCD camera (Hamamatsu Corp., Bridgewater, NJ) connected to a 
Macintosh PowerMac computer, running IPLab image analysis software 
(Scanalytics, Fairfax, VA). The area of CD31-positive cells was calculated as a 
percentage of total area viewed per image [31]. The area of DAB stain as well as 
the total area of the image was quantified using NIH Image software.  
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3.2.8 Statistical Analysis 
We performed Student’s t-tests to determine the statistical significance of 
the differences between results. A significance level of p < 0.05 was used as the 
cutoff (i.e., p values are reported only for cases in which p < 0.05).  
3.3 RESULTS 
3.3.1 GMHA Synthesis and Hydrogel Formation 
While the exact reaction mechanism was not confirmed in these studies, it 
is likely that glycidyl methacrylate reacts with a nucleophilic site on HA, possibly 
by a transesterification reaction similar to the method described for the glycidyl 
methacrylate modification of dextran [34]. 1H-NMR spectroscopy confirmed the 
GMHA reaction, showing acrylate peaks at ~5.6 and ~6.1 ppm and the HA 
methyl peak at 1.9 ppm (Figure 3.3). The spectrum for HA (Figure 3.3a) is 
consistent with published results [35]; the GMHA spectrum (Figure 3.3b) is 
characteristic of the results from multiple reactions (n = 5).  
In a comparison of the two spectrum, there are notable differences in the 
peak heights and shapes. We expect that these differences could be a result of 
methacrylation, and possibly, degradation of the polymer chains during the 
modification reaction. (A detailed investigation of the GMHA structure, however, 
is not within the scope of this study.) Nevertheless, without knowledge of the 
exact structure, it is possible to approximate percent methacrylation, which is  
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Figure 3.3 1H-NMR spectroscopy of HA and GMHA.  
(a) Native HA (2 x 106 molecular weight); (b) GMHA synthesized with 10-fold molar 
excess GM, yielding about 7% methacrylation on native HA. Methyl peaks at ~1.9 ppm 
(denoted by *) are found for native HA and GMHA. Expanded view of ~5.4 to ~6.4 ppm 
display the appearance of (↓) small peaks in (b), indicative of the presence of GM. 
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Table 3.2 Minimum concentrations of Irgacure 2959 and N-vinyl pyrrolidinone 
for GMHA hydrogel formation 
 
% Methacrylation 1 minute UV exposure 5 minutes UV exposure 
 % Irgacure             % VP % Irgacure           % VP    
5 0.05                     0.05 0.05                      0.05 
7 0.05                     0.03 0.03                      0.03 
11 0.01                     0.03 0.01                      0.03 
Irgacure 2959 is a photoinitiator; N-vinyl pyrrolidinone served as a reaction accelerant 
and co-monomer. 
 
 
Table 3.3 Physical properties of GMHA crosslinked hydrogels  
 
% Methacrylation: 5 7 11 
QM  1 52.5 ± 1.6 50.1 ± 4.6 42.5 ± 0.3 
Qv 64.3 61.4 51.9 
cM  (g/mol) 8.45 x 10
5 7.82 x 105 5.92 x 105 
νe (mol/cm3) 1.45 x 10-6 1.57 x 10-6 2.07 x 10-6 
ξ (nm) 644 619 539 
G* (Pa) 2 109.4 ± 16.3 131.3 ± 6.4 154.5 ± 28.2 
 
1 QM for 11% methacrylated GMHA is significantly lower than that for 5% and 7% 
methacrylated GMHA; n = 3.    
 
2 n = 2    Values for QM and G* are mean ± standard deviation.  
 
Abbreviations: glycidyl methacrylate-hyaluronic acid conjugates (GMHA), mass 
swelling ratio (QM), volumetric swelling ratio (Qv), average molecular weight between 
crosslinks ( cM ), effective crosslink density (νe), mesh size (ξ), complex modulus (G*). 
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Figure 3.4 Swelling ratios for GMHA hydrogels.  
The hydrogel swelling ratio, calculated by dividing the swollen gel mass by the dry gel 
mass, is an indicator of the degree of crosslinking in the gel. The swelling ratio for 11% 
methacrylated GMHA hydrogels was significantly lower than that for 5% methacrylated 
(p < 0.001) and 7% methacrylated hydrogels (p < 0.05). Each data point represents the 
average ± SD (n = 3). 
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calculated from the relative integrations of the methacrylate protons and HA’s 
methyl protons [36]. Batches of GMHA made with 6-, 10-, and 20-fold excess 
GM were found to have approximately 5, 7, and 11% methacrylation, 
respectively. The 1H-NMR spectra for the uncrosslinked GMHA on their own are 
not entirely conclusive; thus, further characterizations (e.g., correlate the swelling 
ratio with percent methacrylation) were conducted to confirm the importance of 
the varying degrees of methacrylation. 
 The hydrogels were made by exposing GMHA to UV light in the presence 
of the photoinitiator Irgacure 2959 and N-vinyl pyrrolidinone (a reaction 
accelerant and comonomer). The GMHA liquid crosslinked into materials ranging 
from viscous liquids to brittle solids, depending on the reaction conditions. 
Increasing the percent methacrylation or increasing the concentrations of GMHA, 
Irgacure 2959, or N-vinyl pyrrolidinone, yielded gels with increased firmness. 
Table 3.2 displays the minimum concentrations of Irgacure 2959 and N-vinyl 
pyrrolidinone required for each of the chemistries to form hydrogels in 1 or 5 min 
UV exposure. These minimal concentrations were investigated to confirm that 
gels could be synthesized under cytocompatible conditions, as discussed later.  
3.3.2 GMHA Hydrogel Characterization 
 Three complementary techniques were used to assess the crosslinking 
characteristics of the GMHA hydrogels: swelling ratio determination, Flory-
Rehner calculations, and rheology. The swelling ratio, which varies inversely with 
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the number of methacrylate groups present on GMHA (Figure 3.4), is used in the 
Flory-Rehner theory to calculate the molecular weights between crosslinks, 
effective crosslink densities and mesh sizes (Table 3.3). For 5, 7, and 11% 
methacrylation, the swelling ratios were determined to be 52.5 ± 1.6, 50.1 ± 4.6, 
and 42.4 ± 0.3, respectively (n = 3 for each case). GMHA with 11% 
methacrylation had a significantly lower swelling ratio than GMHA with 5% (p < 
0.001) or 7% (p < 0.05) methacrylation. Generally, as percent methacrylation on 
GMHA increased, the gels showed decreasing swelling ratios, indicating 
increased levels of crosslinking. However, because a small range of percent 
methacrylation values was tested, a more complex relationship between 
methacrylation and the resulting physical properties is not proposed. 
The trend of increased crosslinking with increased methacrylation was 
also apparent in the Flory-Rehner calculations: increased methacrylation 
corresponded to decreased molecular weights between crosslinks (5%: 8.45 x 105 
g/mol, 7%: 7.82 x 105 g/mol, 11%: 5.92 x 105 g/mol), as well as increased 
effective crosslink density (5%: 1.45 x 10-6 mol/cm3, 7%: 1.57 x 10-6 mol/cm3, 
11%: 2.07 x 10-6 mol/cm3) and decreased mesh size (5%: 644 nm, 7%: 619 nm, 
11%: 539 nm). Rheological measurement of the complex modulus (G*, Table 
3.3) further verified this trend: values of G*, while not statistically significant, 
increased slightly as the percent methacrylation increased (5%: 109.4 ± 16.3 Pa, 
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7%: 131.3 ± 6.4 Pa, 11%: 154.5 ± 28.2 Pa), again suggesting increased levels of 
crosslinking.  
3.3.3 In Vitro Degradation of GMHA Hydrogels 
 In vitro degradation rates of the GMHA hydrogels were found by 
incubating hydrogels in three concentrations of hyaluronidase (5, 50, 500 U/ml in 
citrate buffer) and determining the gel masses over time. Enzyme concentrations 
were chosen to approximate endogenous levels (the hyaluronidase concentration 
in human serum is 2.6 U/ml [37]), as well as concentrations 10- and 100-fold 
greater to ensure complete gel degradation before hyaluronidase inactivation 
(hyaluronidase remains active up to 5 h at 37°C) [38].  
Degradation rates (Figure 3.5) were calculated from the initial linear slope 
of gel mass versus time plots (data not shown). At 500 U/ml hyaluronidase, the 
degradation rates of 5% (99.4 ± 8.9 %/h, n = 6) and 7% (105.1 ± 3.6 %/h, n = 6) 
methacrylated GMHA were not statistically different, indicating that 500 U/ml is 
far in excess of the concentration required for controlled degradation. 
Comparisons between hydrogel chemistries were also carried out at 10- to 100-
fold lower concentrations of hyaluronidase. At 5 U/ml hyaluronidase, significant 
differences were measured in the degradation rates: the degradation of 5% 
methacrylated GMHA gels (10.6 ± 2.0 %/h, n = 6) was significantly faster than 
that of 7% methacrylated GMHA gels (4.6 ± 0.8 %/h, n = 5; p < 0.001), and the  
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Figure 3.5 In vitro GMHA hydrogel degradation. 
Degradation rates of GMHA hydrogels with () 5, () 7, and (▲) 11% methacrylation 
in the presence of 5, 50, and 500 U/ml hyaluronidase. GMHA hydrogels with increased 
methacrylation show decreased degradation rates. All comparisons between 
methacrylation conjugates and hyaluronidase concentrations were significantly different 
(p < 0.01), except the comparison of 5% and 7% methacrylated GMHA at 500 U/ml 
hyaluronidase. Each data point represents the average ± SD (n > 4). 
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Figure 3.6 HAEC cytocompatibility in the presence of GMHA hydrogels. 
HAECs were cultured for 24 h and the cell numbers were measured by a colorimetric cell 
viability assay. The absorbance for each sample was normalized to the positive control, 
EGM-2. (a) There was no statistical difference in the cytocompatibility of the 0.1% 
GMHA solution and either EGM-2 or the 0.1% HA solution. (b) Crosslinked GMHA 
hydrogels were made with 0.3% N-vinyl pyrrolidinone (VP) and 1% Irgacure 2959 
(2959), and placed in indirect contact with the cells; the concentration of VP and 2959 
following dilution by the medium was 0.03% and 0.1%, respectively. The hydrogels were 
associated with a decreased cytocompatibility when compared to 0.1% GMHA in 
solution. We also tested solutions of 0.1% GMHA with either 0.03% VP or 0.1% 2959. A 
decreased cytocompatibility was measured for the 0.1% 2959 solution. (c) Next, 
hydrogels with 10-fold less VP and 2959 were tested (0.03% VP and 0.1% 2959 in the 
hydrogel; 0.003% VP and 0.01% 2959 in the medium). There was no statistical 
difference between the cell numbers associated with GMHA solutions and the 
crosslinked GMHA. Also, statistical decreases in cytocompatibility were not found for 
solutions of 0.003% VP and 0.01% 2959 compared to GMHA in solution. Each data 
point represents the mean ± SD (n > 6).  
 82
degradation of 7% was faster than that of 11% methacrylated GMHA gels (0.7 ± 
0.3 %/h, n = 4; p < 0.0001). Similarly, at 50 U/ml hyaluronidase, the degradation 
rate of 5% methacrylated GMHA gels (42.3 ± 7.3 %/h, n = 6) was significantly 
greater than that of 7% gels (25.7 ± 0.6 %/h, n = 6; p < 0.001), and the 
degradation rate of 7% methacrylated GMHA gels was greater than that of 11% 
gels (17.9 ± 3.2 %/h, n = 6; p < 0.001). Therefore, considering the 5- and 50-U/ml 
hyaluronidase results, increasing methacrylation on GMHA resulted in a 
decreased degradation rate, again indicating a correlation between methacrylation 
and the degree of crosslinking. No significant change in mass was observed in the 
negative-control GMHA hydrogels, which were incubated in citrate buffer alone.  
3.3.4 HAEC Cytocompatibility Response to GMHA Hydrogels 
 In vitro HAEC cytocompatibility was measured in response to GMHA 
solutions and crosslinked hydrogels. Cell viabilities were measured after 24 h and 
normalized versus EGM-2. The concentrations for HA, GMHA, Irgacure 2959, 
and N-vinyl pyrrolidinone are reported in this section as effective concentrations 
after dilution by the medium. As shown in Figure 3.6a, no statistically significant 
difference was found between the response to 0.1% GMHA in solution (95.92 ± 
5.31, n = 6) and EGM-2 (100.00 ± 3.37, n = 13). This indicates that the GM 
conjugation chemistry did not have a harsh cytotoxic effect and that the acetone 
precipitation step after the GM modification reaction adequately removed excess 
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GM from the product. Interestingly, 0.1% GMHA had a small but statistically 
significant increase in viability when compared to 0.1% HA (87.83 ± 4.93, n = 6). 
The cytocompatibility effects of crosslinked GMHA were also 
investigated, as shown in Figure 3.6b. When compared to 0.1% GMHA in 
solution, a significant decrease in viability was measured for crosslinked gels 
(final concentration following dilution of 0.1% Irgacure 2959 and 0.03% N-vinyl 
pyrrolidinone; 78.42 ± 4.58; p < 0.001). Treatments at a final dilution of 0.1% 
GMHA with either 0.1% Irgacure 2959 or 0.03% N-vinyl pyrrolidinone were also 
tested. When compared to 0.1% GMHA in solution, no decrease in viability was 
measured for 0.03% N-vinyl pyrrolidinone (100.44 ± 7.66). However, a 
statistically significant decrease was measured for 0.1% Irgacure 2959 (61.16 ± 
5.77, p < 0.0001). These results indicate that Irgacure 2959 may play a role in the 
decreased cytocompatibility of GMHA hydrogels synthesized under these 
conditions.  
Next, hydrogels with 10-fold less Irgacure 2959 and N-vinyl pyrrolidinone 
were tested. As shown in Figure 3.6c, no statistically significant decrease in 
viability (compared to GMHA in solution) was measured for hydrogels made with 
0.03% N-vinyl pyrrolidinone and 0.1% Irgacure 2959 (concentrations following 
dilution of 0.003% and 0.01%, respectively; 94.19 ± 4.45). Similar results were 
found for 0.1% GMHA solutions with 0.003% N-vinyl pyrrolidinone (109.14 ± 
8.26) and 0.01% Irgacure 2959 (96.90 ± 10.03).  
 84
 
Figure 3.7 HAEC proliferation response to degraded GMHA fragments.  
HAECs were cultured in 1.5 µg/ml of HA fragments or GMHA fragments (5, 7, 11% 
methacrylation) in starvation medium for 48 h. EGM-2 provided a positive control and 
heat-inactivated hyaluronidase in starvation medium was a negative control. Cell 
viabilities, which were measured via absorbance in a colorimetric cell viability assay, 
were normalized to the heat-inactivated hyaluronidase control. No statistical difference 
was found in the proliferation response to HA fragments and GMHA fragments for all 
values of methacrylation, indicating that glycidyl methacrylate modification of HA does 
not significantly reduce its biological activity. The proliferation response to HA and 
GMHA fragments was significantly greater than the response to hyaluronidase and 
significantly less than the response to EGM-2 (p < 0.001). Each data point represents the 
mean ± SD (n > 9). 
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Figure 3.8 GMHA implants in rats.  
Hydrogels were implanted subcutaneously in rats for 2 weeks. (a) Agarose negative 
controls, (b) 7% GMHA hydrogels ( denotes areas of hydrogel), and (c) fibrin positive 
controls were stained with hematoxylin and CD31, a marker for endothelial cells. No 
significant difference was found in the numbers of endothelial cells present in the GMHA 
(7.06 ± 0.14 % area CD31-positive cells, n = 4) or in the fibrin (6.63 ± 1.10 % area 
CD31-positive cells, n = 9) hydrogels. No endothelial cells were associated with the 
agarose controls. Scale bar, 200 µm. 
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Our findings were similar to those involving the cytotoxicity effects of 
Irgacure 2959 (also called Darocur 2959) on fibroblasts [39]. At 48 h, Bryant et 
al. found that fibroblasts treated with 0.01% Darocur 2959 had a survival rate 
similar to those without treatment and that treatment with 0.1% Darocur 2959 
yielded a slight decrease in viability. Although there were marked differences in 
the experimental procedures (e.g., cell type used), our study verified the general 
trend of increased cytotoxicity associated with increased Irgacure 2959 
concentrations.  
3.3.5 HAEC Proliferation Response to GMHA Hydrogels 
The HAEC proliferation response to degraded HA and GMHA is reported 
in Figure 3.7. Since we wanted to examine GMHA's ability to promote 
endothelial cell proliferation relative to unmodified HA, GMHA was not 
crosslinked, and Irgacure 2959 and N-vinyl pyrrolidinone were not included in the 
proliferation experiments. We measured relative cell viabilities using methods 
similar to those in the cytocompatibility studies except that the absorbance values 
were normalized to the negative control: heat-inactivated hyaluronidase in 
starvation medium. Values for HA and all GMHA fragments tested were 
statistically similar to each other and statistically greater than that for the 
hyaluronidase negative control, indicating that there was an increased 
proliferation response to HA and that there was no significant loss of activity as a 
result of the conjugation chemistry. However, proliferation rates in the presence 
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of HA and GMHA fragments did not increase to the levels of the fully 
supplemented EGM-2 positive control (p < 0.001 in all cases), probably because 
the HA and GMHA fragments were diluted in the starvation medium and did not 
contain all of the appropriate factors required for optimal growth. Yet HA and all 
GMHA conjugates showed HAEC proliferation rates higher than that of the 
negative control, in general agreement with published studies of HA fragments 
[30].  
3.3.6 GMHA Implants 
To investigate the in vivo endothelial cell response to the crosslinked 
GMHA, we implanted hydrogels of 7% methacrylated GMHA subcutaneously in 
rats. After 2 weeks, the TECs were removed, and the tissue contained in the 
construct was harvested, cryosectioned, and stained with CD31-DAB and 
hematoxylin. Agarose (Figure 3.8a) was not infiltrated by cells and thus served as 
a suitable negative control. Cellular migration into the gel interstices was detected 
in the GMHA implants (Figure 3.8b), indicating that cells were attaching to and 
degrading the edge of the GMHA hydrogels. Inflammation, which was anticipated 
because of the biological activity of HA [14] was present but minimal. Although 
the GMHA hydrogels were not completely degraded at two weeks, the fibrin 
hydrogels (Figure 3.8c) were entirely degraded. The tissues in the fibrin TECs 
were well infiltrated by cells and highly vascularized. The percent endothelial 
cells at the edge of the implant measured for GMHA hydrogels (7.1 ± 0.1, n = 4) 
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was statistically indistinguishable from that for fibrin (6.6 ± 1.7, n = 9), indicating 
that both materials promoted similar levels of interactions with endothelial cells.  
3.4 DISCUSSION 
 HA presents unique advantages for synthesizing healable scaffolds 
because of its prominent role in wound healing, as well as its natural 
biodegradability, ease of production and modification, and hydrophilic and 
nonadhesive character. Furthermore, while most natural and synthetic 
biomaterials possess relatively few functional side groups, HA has three reaction 
groups: hydroxyl, carboxyl, and acetamido. These reaction sites lend versatility to 
HA for modification with chemically crosslinkable groups and bioactive moieties. 
The aim of the research presented in this chapter was to take advantage of these 
distinctive properties to create a novel tissue engineering scaffold. 
A variety of chemical reactions exist for HA modification (e.g., 
esterification, nitration, acetylation) and polymerization (based on formaldehyde, 
epoxide, polyisocyanate, vinyl sulfone, or carbodiimide) [18]. Bulpitt and 
Aeschlimann (1999) developed an in situ polymerizable HA for articular cartilage 
applications by synthesizing HA-aldehyde or HA-amine derivatives and 
crosslinking the derivatives with a variety of commercially available crosslinkers, 
such as bifunctional esters, and glutaraldehyde. Although this method produces 
HA hydrogels with a variety of properties and degradation rates, there are 
disadvantages: the modification procedure involves many synthesis and 
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purification steps, and the crosslinking reaction occurs immediately upon mixing 
the solutions of modified HA and crosslinker. Because HA forms highly viscous 
solutions, we have found that the crosslinking chemistries that occur upon mixing 
are hard to control and yield inconsistent gels. 
Use of photopolymerizable methacrylate groups presents several 
advantages over other crosslinking methods. Specifically, photopolymerization 
avoids the disadvantages stemming from reactions that occur immediately upon 
solution mixing and those that depend on pH, ionic strength, or temperature. With 
photopolymerization, the solutions can be completely mixed before exposure to 
the appropriate wavelength of light, yielding a rapid, controllable, and minimally 
invasive crosslinking method [13,19]. Furthermore, photopolymerization can be 
performed under physiological conditions, which allows for either the 
copolymerization of bioactive molecules or the incorporation of cells. Many 
photopolymerization chemistries are known, but they have primarily been 
investigated with nondegradable synthetic polymers [13]. 
 Several methods have been introduced for synthesizing methacrylate-
modified HA, one using methacrylic anhydride [36] and others with glycidyl 
methacrylate (GM) [29,40]. We have found that the GM modification consistently 
yields methacrylate-modified HA, and that the addition of triethylamine and 
tetrabutyl ammonium bromide, a phase-transfer catalyst, permits a faster reaction 
of aqueous HA with the nonaqueous GM. We have also used acetone 
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precipitation to rinse out the unused reactants from GMHA, thereby avoiding the 
lengthy dialysis procedures used in other methods [29,40]. HAEC 
cytocompatibility and proliferation studies (discussed later) suggest that the 
excess glycidyl methacrylate, a known cytotoxic chemical, is adequately rinsed 
from the GMHA conjugates by the acetone precipitation step.  
 In our study, physical characterization of the GMHA hydrogels revealed 
that increasing levels of methacrylation could be used to fine-tune the swelling 
ratio (Figure 3.4), crosslink density, mesh size and complex modulus (Table 3.3), 
and degradation rate (Figure 3.5) within a modest range. However, we feel that 
manipulating any of the system variables (e.g., percent methacrylation, choice and 
concentration of photopolymerization reactants) will yield gels with a broader 
range of properties and increased cytocompatibility. For example, the range of 
degradation rates achieved in vitro could be broadened by variations in the 
crosslink density, as described above, or by the incorporation of hyaluronidase in 
the polymerization solution (yielding faster degradation rates).    
The cytocompatibility of GMHA hydrogels is critical to the ultimate 
success of wound healing. We have found no statistically significant decrease in 
the in vitro HAEC cytocompatibility associated with the GMHA conjugates in 
solution (Figure 3.6). Treatments containing N-vinyl pyrrolidinone and GMHA 
in solution yielded cytocompatibilities statistically similar to that of EGM-2. 
However, we did note significant decreases in cell viability associated with 
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GMHA in the presence of higher concentrations of Irgacure 2959, similar to 
published work with fibroblasts [39]. Nonetheless, compared with results of a 
recent in vitro study of smooth muscle cell cytotoxicity in response to 
photopolymerizable HA [29], the GMHA hydrogels presented here were much 
more cytocompatible.  
Once the range of cytocompatible concentrations of Irgacure 2959 and N-
vinyl pyrrolidinone were determined, we sought to reconfirm that hydrogels can 
indeed be synthesized under such conditions (Table 3.2). It should be noted that 
in the cytotoxicity studies, Irgacure 2959 and N-vinyl-pyrrolidinone are diluted 
10-fold by the cell culture medium. Therefore, the gels presented in Figure 3.6c 
were made with 0.1% Irgacure 2959 and 0.03% N-vinyl pyrrolidinone. The 
minimum amount of Irgacure 2959 and N-vinyl pyrrolidinone required for 
hydrogel formation was 0.01% and 0.03%, respectively (for 11% methacrylated 
GMHA, the same percentage used in the cytocompatibility studies). In other 
words, for the case of 11% methacrylated GMHA, the concentrations found to be 
cytocompatible were equal to or greater than the concentrations required for 
hydrogel formation. 
 To use crosslinked GMHA as a healable biomaterial, HA’s intrinsic 
biological activity and role in wound healing must be retained after the 
methacrylate modification reaction. In the in vitro HAEC proliferation assay that 
we used to investigate the biological activities of HA and GMHA fragments, the 
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proliferation rate was enhanced by 20% in the HA fragments over the negative 
control (Figure 3.7); furthermore, no statistical difference was found in the native 
HA and the various GMHA methacrylation chemistries. Although this was the 
only in vitro method used to gauge GMHA’s retention of HA’s biological 
activity, it was a promising start for follow-up studies exploring the effects of 
methacrylation modifications on biologically active polymers. 
 In the rat subcutaneous implants used to determine the in vivo cellular 
response to the GMHA hydrogels (Figure 3.8), a small inflammatory response 
was associated with the GMHA implants; this response, however, is expected 
with high concentrations of HA and is vital for the initiation of wound healing. 
Also, endothelial cells infiltrated the GMHA gels, and comparable levels of these 
CD31-positive cells were present in both the fibrin-positive controls and the 
GMHA hydrogels. Future work in this area includes further modification of 
GMHA to promote controlled endothelial cell infiltration; for example, binding 
HA’s carboxyl groups to the amino termini of adhesive peptide sequences, 
extracellular matrix molecules or growth factors via 1-ethyl-
(dimethylaminopropyl) carbodiimide-mediated reactions such as those reported 
for peptide-alginate composites [41].  
 In conclusion, we report a simple method for synthesizing glycidyl 
methacrylate-HA conjugates. The resulting GMHA polymers were 
cytocompatible, photopolymerizable, and biodegradable, and they retained HA’s 
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intrinsic biological activity in promoting endothelial cell proliferation. 
Furthermore, the GMHA hydrogels were comparable to fibrin in the extent to 
which the materials promoted interactions with endothelial cells in rat 
subcutaneous implants. GMHA hydrogels are, we believe, promising candidates 
for tissue engineering constructs that support wound healing.  
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Chapter 4: GMHA-PEG-Peptide Composite Hydrogels 
As discussed in Chapter 3, we created photocrosslinkable glycidyl 
methacrylate-hyaluronic acid (GMHA) hydrogel biomaterials that were 
cytocompatible, biologically active, and resistant to enzymatic degradation by 
hyaluronidase. The goal of the studies presented in this chapter was to further tune 
the material and biological properties of the GMHA hydrogels.  
We conjugated GMHA with acrylated forms of polyethylene glycol (PEG) 
and PEG-peptides to yield GMHA-PEG-peptide composite hydrogels. By varying 
the reactant concentrations, we created solid hydrogels with high peptide 
conjugation efficiencies (up to 80%), controllable peptide concentrations (in the 
range of 1 - 6 µmol peptide per ml hydrogel), and defined physicochemical 
properties (e.g., swelling ratio, enzymatic degradation rate). Furthermore, when 
modified with a peptide containing the adhesive peptide sequence RGD, the 
GMHA-PEG-peptide composites are able to support increased levels of human 
fibroblast adhesion compared to GMHA-PEG hydrogels alone. These composite 
hydrogels may prove to be a promising scaffolding biomaterial for a variety of 
soft tissue engineering applications.  
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4.1 INTRODUCTION 
HA, a naturally occurring glycosaminoglycan, offers many unique 
advantages as a building block for biomaterials [1]. For example, HA is non-
immunogenic, enzymatically degradable, and relatively non-adhesive to cells and 
proteins [2,3]. Physiologically, HA plays a role in several processes, including 
angiogenesis, extracellular matrix homeostasis, wound healing, and the mediation 
of long-term inflammation [2]. Furthermore, HA is particularly suitable for 
biomaterial fabrication as it can be produced in large quantities through bacterial 
fermentation [3], thus avoiding the risk of the animal-derived pathogens that are 
possibly associated with naturally derived materials.  
As discussed in Chapter 3, we have modified HA with glycidyl 
methacrylate, yielding a photocrosslinkable conjugate, GMHA [4]. The resulting 
polymers are cytocompatible, biologically active, and can be photocrosslinked to 
form GMHA hydrogels with tunable material properties (e.g., degradation rate, 
crosslink density). When implanted subcutaneously in rats, the GMHA hydrogels 
were associated with similar levels of vascularization at the implant edge as fibrin 
positive controls. However, in vitro studies of endothelial cell adhesion indicated 
that the GMHA hydrogels alone do not support cell adhesion and spreading 
(unpublished data). These in vitro results are in agreement with published work 
with similar crosslinked HA hydrogels [5], and given HA's highly hydrated and 
non-adhesive nature, these in vitro results are not unexpected. 
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A specific goal of the work presented in this chapter was to modify 
GMHA with peptide sequences, such as the cell adhesive fibronectin-derived 
sequence RGD (Arg-Gly-Asp). Work with other nonadhesive hydrogels such as 
polyethylene glycol (PEG) [6,7], and alginate [8] have demonstrated that 
covalently bound peptide sequences can be used to specifically tune cellular 
adhesion, migration, and proliferation. Fortunately, GMHA has several possible 
sites for modification, including carboxyl, hydroxyl, and acetamido groups found 
naturally on HA in addition to the conjugated photoreactive methacrylate groups.  
Other researchers have also created crosslinked HA-RGD conjugates. For 
example, Glass, et al. [9] reported a periodate oxidation method to conjugate 
RGD onto HA hydrogel matrices. The RGD-HA matrices were associated with 
higher levels of osteoscarcoma cell adhesion and proliferation. However, 
periodate oxidation of HA opens ring structures in the glucuronic acid moieties of 
the polymer backbone; such changes may result in decreased biological activity or 
otherwise altered physicochemical properties [10]. Very recently, the Hubbell 
laboratory published an extensive study of the mechanical properties of HA-based 
hydrogels for cartilage repair [5]. The hydrogels were reinforced with low 
molecular weight PEG diacrylate and functionalized with acrylated PEG-RGD 
conjugates that were created through Michael-type addition chemistry. These 
examples of crosslinked HA-RGD conjugates demonstrate the growing interest in 
HA as scaffold materials for tissue engineering applications. 
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We created GMHA-peptide conjugates for soft tissue engineering 
applications (e.g., nerve regeneration, wound healing). To conserve cost, the 
model peptide hexaglycine (Gly-Gly-Gly-Gly-Gly-Gly) was used to develop three 
methods for GMHA conjugation. The most efficient method yielded a GMHA-
PEG-peptide composite hydrogel, which was characterized in terms of its 
swelling and degradation properties. Finally, GMHA-PEG-RGD composites were 
preliminarily explored for their ability to support in vitro fibroblast adhesion. 
4.2 MATERIALS AND METHODS 
All materials were acquired from Sigma-Aldrich (St. Louis, MO), unless 
otherwise noted. 
4.2.1 GMHA Conjugates 
We synthesized GMHA conjugates using previously developed methods 
[4] (see also Chapter 3 and the detailed protocol in Appendix A.1). Briefly, we 
prepared GMHA with 11% methacrylation by reacting a 1% (w/v) solution of 
fermentation-derived HA (~2 x 106 molecular weight, Clear Solutions Biotech, 
Stony Brook, NY) in distilled water with 20-fold molar excess of glycidyl 
methacrylate in the presence of excess triethylamine and tetrabutyl ammonium 
bromide. The reaction was mixed overnight at room temperature and then for 1 h 
at 60°C. Finally, the GMHA was precipitated in acetone and dissolved in 
deionized water twice and then lyophilized.  
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Figure 4.1 Schematic of peptide conjugation chemistries.  
Three approaches were evaluated as means of covalently binding peptides (a) to 
uncrosslinked GMHA and (b, c) during the hydrogel crosslinking reaction. (a) 
GMHA, drawn schematically to denote the carboxylate groups (-COO-) and 
methacrylate groups (4-point stars), is conjugated with peptides by a reaction 
mediated by EDC and an ester-activating agent (either NHS or HOBt). To 
incorporate peptides during the hydrogel photocrosslinking, acrylated PEG-
peptides (acrylate groups are denoted by 5-pointed stars) are mixed with (b) 
GMHA alone or (c) GMHA and acrylated 4-arm PEG. The acrylated 4-arm PEG 
increases the total number of photoreactive groups in the hydrogel, effectively 
increasing the number of available sites for crosslinking and reaction with 
acrylated PEG-peptides. 
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4.2.2 EDC-Mediated GMHA-Peptide Conjugation 
 We conjugated the model peptide hexaglycine onto uncrosslinked GMHA 
using an EDC-mediated reaction [8,10] (shown schematically in Figure 4.1a; for 
a detailed protocol see Appendix A.7). All steps were carried out at room 
temperature. Solutions of 1% (w/v) GMHA were prepared in buffered pH 4.5 - 
7.5 solutions that contained 0.1 M morpholinoethanesulfonic acid (MES) and 0.3 
M NaCl. 1-hydroxybenzotriazole hydrate (HOBt; American Peptide, Sunnyvale, 
CA) or N-hydroxysuccinimide (NHS) was added at a 0.25, 0.5 or 1 molar ratio to 
GMHA's carboxylates and mixed for 5 min. Next, EDC (0.1, 0.5, 2 or 4 molar 
ratio to GMHA's carboxylates) was added and mixed for 5 min. Finally, 
hexaglycine (1.0 - 2.0 molar ratio to GMHA's carboxylates) was added and mixed 
for 2 h. The reaction was transferred to 7000 molecular weight cut-off dialysis 
tubing (Pierce, Rockford, IL), dialyzed overnight against distilled deionized water 
(20 times the volume of the reaction) and lyophilized. The extent of hexaglycine 
conjugation was determined with a ninhydrin assay as described later. 
4.2.3 Photocrosslinked GMHA-PEG-Peptide Hydrogels 
 We also used an acrylated PEG-peptide method [6] to conjugate 
hexaglycine to GMHA during the crosslinking reaction. To synthesize the 
acrylated PEG-hexaglycine, 62 µmol of hexaglycine (2.24 ml of a 10 mg/ml stock 
solution of hexaglycine in 1 M HCl) was added to 15 ml of 50 mM sodium 
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bicarbonate buffer, pH 8.5. The pH was readjusted to 8.5 with approximately 2.2 
ml of 1 M NaOH. Next, 62 µmol (0.2 g) of dry acryloyl-PEG-NHS (Nektar 
Therapeutics, Huntsville, AL) was added to the hexaglycine solution and mixed 
immediately to dissolve. The reaction was mixed for 2 h at room temperature, 
transferred to 1000 molecular weight cut-off dialysis tubing (Spectrum 
Laboratories, Rancho Dominguez, CA), and dialyzed overnight against distilled 
deionized water (20 times the volume of the reaction solution). The product was 
lyophilized and stored desiccated at -20 °C. The conjugation was verified by 
determining the mass of the product with Matrix-Assisted Laser 
Desorption/Ionization Mass Spectrometry (MALDI-MS). For a detailed protocol 
for conjugating peptides to acryloyl-PEG-NHS, see Appendix A.8. 
The crosslinked GMHA-PEG-peptide hydrogels were synthesized by two 
reaction schemes. In the first scheme (Scheme I; shown schematically in Figure 
4.1b), we exposed a mixture of GMHA (1% w/v or ~2.3 µmol photoreactive sites 
per ml in phosphate-buffered saline) and acrylated PEG-hexaglycine 
(approximately 1.0 - 30.0 µmol/ml) to UV light (365 nm, ~22 mW/cm2, 60 s 
exposure) in the presence of the photoinitiator Irgacure 2959 (1% w/v, Ciba 
Specialty Chemicals, Basel, Switzerland) and N-vinyl pyrrolidinone (0.3% v/v). 
The second scheme (Scheme II; Figure 4.1c), is similar to Scheme I, except that 
we also added acrylated 4-arm PEG (MW 10,000; SunBio, Walnut Creek, CA) to 
increase the total number of photoreactive sites available in the hydrogel. The 
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concentrations of acrylated 4-arm PEG were 0.5, 3.5, and 4.6% (w/v), which 
correspond to approximately 2.1, 13.4, and 17.5 µmol photoreactive sites per ml. 
4.2.4 Ninhydrin Assay 
To verify the moles of peptide bound to uncrosslinked GMHA (EDC-
mediated GMHA conjugation) and crosslinked GMHA-PEG-peptide hydrogels, 
we used the ninhydrin assay to measure the concentration of free amino acid in 
hydrolyzed samples [11,12] (for a detailed protocol see Appendix A.9). The 
samples and peptide standards were hydrolyzed at 1 mg/ml in 13.5 M NaOH in an 
autoclave (at least 40 min at 121-125°C). Next, 12.1 M HCl was carefully added 
drop-wise to neutralize the base. The volume was measured and the sample 
concentration was recorded. The hydrolyzed solution was diluted to 50 µg/ml in 
0.1 M citric acid buffer, pH 4.7. The pH was measured and adjusted, if necessary.  
To prepare the ninhydrin reagent, stock solutions of stannous chloride 
(100 mg/ml in ethylene glycol) and 4 N acetate buffer (pH 5.5-8.0) are required. 
The 4 N acetate buffer was made by dissolving 54.4 g sodium acetate in 100 ml 
acetic acid and then adjusting the total volume to 500 ml with distilled deionized 
water. The ninhydrin reagent was freshly prepared by dissolving 0.2 g ninhydrin 
in 7.5 ml ethylene glycol and 2.5 ml 4 N acetate buffer. Then 250 µl of stannous 
chloride solution was added with mixing. The ninhydrin reagent was only used 
while it was pale red in color.  
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In a 96-well plate, 80 µl of the hydrolyzed samples or standards and 80 µl 
of the ninhydrin reagent were added per well. All samples were prepared in 
triplicate. The well plate was covered with sealing tape (Corning Costar, Acton, 
MA) and incubated at 95-100°C in a water bath for 10 min. The absorbance of 
each well was read at 595 nm using a microplate reader (Biotek Instruments, 
Winooski, VT) and the amino acid content of each sample was calculated from a 
standard curve. 
4.2.5 Swelling Ratio 
To investigate the relative degrees of crosslinking in the hydrogels, we 
determined the swelling ratio of each sample using published methods [4] (for 
additional information, see Chapter 3 and the detailed protocol in Appendix 
A.2). The swelling ratio is inversely related to the extent of crosslinking and was 
calculated by dividing the gel mass after swelling (Ms) by the dry gel mass (Md). 
A Perkin-Elmer (Wellesley, MA) thermogravimetric analyzer (TGA) was used to 
measure Ms and Md. The hydrogels were preswollen in phosphate-buffered saline 
overnight and a small piece (10-20 mg) was placed in the TGA weighing pan. The 
initial mass was recorded as Ms, and the sample was heated slowly to 100°C until 
a constant mass was achieved. The final mass obtained was recorded as Md.  
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4.2.6 In Vitro Degradation by Hyaluronidase 
We determined the enzymatic degradation rate of GMHA-PEG hydrogels 
using previously developed methods [4] (for a detailed protocol see Appendix 
A.3). Solutions of GMHA (1%, w/v) and acrylated 4-arm PEG (0.3, 0.6, 1.2, or 
4.6%, w/v) were photocrosslinked in 8-mm diameter, 2-mm deep perfusion 
chamber molds (Sigma-Aldrich). The hydrogels were transferred to 24-well plates 
and soaked in citrate buffer (0.15 M NaCl, 0.15 M Na2HPO4-7H20, 0.03 M citric 
acid, pH 5.3) overnight. The gels were removed and the gel masses were 
recorded. Bovine testicular hyaluronidase in citrate buffer (1.0 ml of 5 U/ml) was 
added to each gel and incubated at 37°C with mixing on a shaker. Every 2 h, the 
solution was removed and the gel masses were determined. GMHA-PEG 
hydrogels in citrate buffer without hyaluronidase were used as negative controls. 
4.2.7 Cell Adhesion 
We studied the ability of enzymatically degradable GMHA-PEG-peptide 
hydrogels (Scheme II; 1% GMHA, 0.5% acrylated 4-arm PEG, 0.1% Irgacure 
2959, 0.03% N-vinyl pyrrolidinone) to support in vitro fibroblast adhesion. A 
composite of GMHA-PEG-GRGDSG (Gly-Arg-Gly-Asp-Ser-Gly; ~90% purity, 
synthesized by the Institute for Cellular and Molecular Biology Core Facility at 
The University of Texas at Austin) was compared to two negative control 
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hydrogels, GMHA-PEG and GMHA-PEG-hexaglycine. Each peptide was 
examined at 1.5 and 5 µmol/ml hydrogel. 
To create a thin, flat hydrogel, 50 µl of gelation solution was placed on an 
18 x 18 mm square No. 2 coverslip and covered with a 12 mm diameter circular 
No. 1 coverslip. The entire assembly was exposed to UV light for 2 minutes and 
then the coverslips were carefully separated in opposite parallel directions. In 
most cases, the hydrogel adhered to the top circular coverslip. If the hydrogel was 
homogeneous in appearance (no bubbles or tearing) and covered approximately 
75% of the coverslip, it was placed in a well of a 12-well plate. The hydrogels that 
were torn or loosely adhered to the coverslip were excluded. The coverslips with 
adherent hydrogels (three samples of each hydrogel composite type) were 
sterilized for 10 min under UV light in a laminar flow tissue culture hood and 
then carefully washed for 5 min each in sterile PBS and Clonetics' fibroblast 
growth media-2 (FGM-2).  
Clonetics adult normal human dermal fibroblasts (Cambrex, Walkersville, 
MD) were obtained at passage 1, used at passage 4, and maintained in FBM-2. In 
1.5 ml of medium, 80,000 cells were seeded per well onto the hydrogels. After 72 
hours incubation, the hydrogels were carefully washed with PBS and then the 
cells were imaged at 10x magnification under phase contrast using an Olympus 
IX-70 inverted microscope (Melville, NY). Cells adherent to the hydrogels were 
counted in at least three 6.6 mm2 views per sample.  
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4.2.8 Statistical Analysis 
We used Student's t-tests to find the statistical significance of the 
differences between results. A significance of p < 0.05 was used as the cutoff. 
4.3 RESULTS 
Three approaches (Figure 4.1) were examined as means of covalently 
binding peptides to GMHA. To conserve cost, hexaglycine was used as a model 
peptide and each approach was optimized for maximal conjugation efficiency.  
4.3.1 EDC-Mediated GMHA-Peptide Conjugation 
 An EDC-mediated reaction was used to covalently link hexaglycine onto 
uncrosslinked GMHA. We investigated five reaction variables: pH, the choice and 
moles of ester-activating agent (e.g., NHS or HOBt) and the moles of EDC and 
hexaglycine. The moles of NHS, HOBt, EDC, and hexaglycine used in the 
reactions were expressed as the molar ratio of the component to the moles of 
GMHA's carboxylates (designated, for example, as EDC:GMHA -COO-). A 
ninhydrin assay was used to measure hexaglycine conjugation for at least 2 
hydrolyzed samples for each condition.  
First, we examined the effect of reaction pH on EDC-mediated reactions 
in the presence of NHS or HOBt (Figure 4.2a). Reactions were carried out with 
0.5 EDC:GMHA -COO-, 0.25 NHS:GMHA -COO- or 0.25 HOBt:GMHA -COO-, 
1 hexaglycine:GMHA -COO-, and pH values of 4.5, 5.5, 6.5, and 7.5. Reactions 
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that were carried out at pH 5.5 had the greatest conjugation efficiencies (NHS: 2.6 
± 0.5%, n = 6; HOBt: 3.0 ± 0.7%, n = 3) and were statistically different than the 
negative control (no EDC, NHS or HOBt: 0.4 ± 0.3%, n = 3). Reactions with 
NHS at pH 4.5 (1.5 ± 0.5%, n = 5) and pH 6.5 (1.8 ± 0.8%, n = 6) were also 
statistically different than the negative control.  
Next, the effect of EDC:GMHA-COO- was investigated (Figure 4.2b). 
Reactions were completed with 0.25 HOBt:GMHA -COO-, 1 hexaglycine:GMHA 
-COO-, and at pH 5.5. All efficiencies were statistically different from the 
negative control. For EDC:GMHA -COO- values of 0.l, 0.5, 2, and 4, the 
respective efficiencies were 4.4 ± 1.2% (n = 4), 3.0 ± 0.7% (n = 3), 2.7 ± 0.5% (n 
= 4), and 1.4 ± 0.6% (n = 4). For reactions with 0.1 EDC:GMHA -COO-, the 
conjugation efficiency is greater, but not statistically distinct from reactions 
carried out with a 0.5 EDC:GMHA -COO-. Similarly, for reactions with 0.5 
EDC:GMHA -COO-, the conjugation efficiency is greater, but not statistically 
different than reactions carried out at 2.0 EDC:GMHA -COO-. It may seem 
unexpected that efficiency would decrease with increasing EDC concentrations. 
However, it should be noted that 0.25 HOBt:GMHA -COO- was used in each 
case. When the concentration of EDC is roughly equal to the concentration of 
HOBt, the efficiencies were higher than when EDC is in excess of HOBt. This 
trend reinforces published work [10], suggesting the importance of ester-
activating agents in EDC-mediated HA modification reactions. 
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Figure 4.2 Efficiency of EDC-mediated GMHA-peptide conjugations.  
The model peptide hexaglycine was conjugated onto uncrosslinked GMHA by 
EDC-mediated reactions. Shown are the results of three reaction variables:  
reaction pH, the choice of ester-activating agent (NHS, open bars; HOBt, shaded 
bars), and the molar ratio of EDC to GMHA's carboxylate groups. (a) Reactions 
that were carried out at pH 5.5 had the greatest conjugation efficiencies and were 
statistically greater than the negative control (no EDC, NHS or HOBt; hatched 
bar). Reactions with NHS at pH 4.5 and pH 6.5 were also statistically greater than 
the negative control. (b) The effect of the molar ratio of EDC to GMHA's 
carboxylate groups was investigated for reactions in the presence of HOBt. All 
efficiencies were statistically different from the negative control. Each bar 
represents the average plus the standard deviation.  
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The remaining variables (i.e., moles of ester activating agent and 
hexaglycine) were investigated at pH 5.5 and with a constant 0.5 EDC:GMHA -
COO-. We found that with 1 hexaglycine:GMHA -COO- and NHS:GMHA -COO- 
or HOBt:GMHA -COO- varying from 0.25 to 1, the conjugation efficiencies were 
not statistically different and were all in the range of 1 - 3 % (data not shown). 
Likewise, with 0.25 HOBt:GMHA -COO- and hexaglycine:GMHA -COO- from 
0.5 to 2, the differences in conjugation efficiencies were not statistically 
significant and were in the range of 1 - 3% (data not shown).  
4.3.2 Photocrosslinked GMHA-PEG-Peptide Hydrogels 
 To incorporate the model peptide hexaglycine into GMHA hydrogels 
during the crosslinking reaction, two general reaction schemes were developed. 
For each scheme, we sought a chemistry that would yield solid hydrogels and 
conjugated peptide yields in the range of 1-5 µmol/ml (based on the range found 
to be optimal for cell adhesion and migration in similar hydrogel systems 
[7,13,14]).   
In Scheme I, the effect of varying acrylated PEG-hexaglycine 
concentration was evaluated in gelation solutions of 1% (w/v) GMHA, 1% 
Irgacure 2959, and 0.3% (v/v) N-vinyl pyrrolidinone. For acrylated PEG-
hexaglycine input concentrations above 1.4 µmol/ml, solid hydrogels did not 
form. We presume that in these cases, the number of photocrosslinkable sites 
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available on GMHA alone is not sufficient to support crosslinking as well as 
peptide conjugation. In previous work [4], we have found that 11% 
methacrylation is the highest extent of modification achievable under the chosen 
reaction conditions. Therefore, we sought another method of increasing the 
number of available photocrosslinkable sites within the gelation solution. 
In Scheme II, we supplemented the total number of available 
photoreactive groups by adding acrylated 4-arm PEG to the gelation solutions 
from Scheme I. The hydrogel samples were hydrolyzed and the ninhydrin assay 
was used to determine the mass of conjugated hexaglycine. From this 
information, the conjugation efficiency (i.e., the percent of the input hexaglycine 
that is conjugated to the hydrogel) and yield (i.e., the concentration of peptide 
conjugated to the hydrogel) were calculated. In Figure 4.3, a single data set is 
shown for three concentrations of total hydrogel reactive sites (4.4, 15.7, and 19.8 
µmol/ml), which are plotted versus the hexaglycine concentration in the gelation 
solution (Figure 4.3a,c) and the molar ratio of input hexaglycine to hydrogel 
reactive sites (Figure 4.3b,d). Efficiency was found to vary inversely with the 
moles of hexaglycine, the total number of reactive sites, and the ratio of 
hexaglycine to hydrogel reactive sites. Yield, on the other hand, increased with 
increasing hexaglycine put into the reaction, the total number of reactive sites, and 
the ratio of hexaglycine to hydrogel reactive sites.  
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Figure 4.3 Efficiency and yield of GMHA-PEG-peptide conjugate hydrogels.  
Composite hydrogels were synthesized with 1% (w/v) GMHA and varying 
amounts of acrylated 4-arm PEG and acrylated PEG-hexaglycine. The mass of 
hexaglycine conjugated was determined with the ninhydrin assay and used to 
calculate conjugation (a,b) efficiency (i.e., the percent of the input hexaglycine 
that is conjugated to the hydrogel) and (c,d) yield (i.e., the concentration of 
peptide conjugated to the hydrogel). A single data set is shown for 3 
concentrations of hydrogel reactive sites (○, 4.4 µmol /ml; ■, 15.7 µmol /ml; ◆, 
19.8 µmol /ml) and are plotted versus (a,c) µmol of hexaglycine input per ml of 
gelation solution and (b,d) molar ratio of input hexaglycine to hydrogel reactive 
sites.  
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Figure 4.4 Swelling ratio of GMHA-PEG-peptide hydrogels.  
The swelling ratio, calculated by the ratio of the swollen mass to the dry mass of a 
hydrogel, is inversely related to the hydrogel crosslink density. The swelling 
ratios for hydrogels with 4.4 µmol/ml reactive sites (○) are statistically greater 
than the hydrogels with either 15.7 (■) or 19.8 (◆) µmol/ml reactive sites. The 
difference in swelling ratios between the hydrogels with 15.7 µmol reactive sites 
per ml is not statistically distinct from the hydrogels with 19.8 µmol reactive sites 
per ml. Within each set of hydrogels with equal numbers of gel reactive sites, the 
differences in swelling ratios are not statistically significant. Each point represents 
the average ± standard deviation.  
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4.3.3 Swelling Ratio 
To evaluate the effect of acrylated 4-arm PEG and PEG-hexaglycine on 
the relative extents of crosslinking, we determined the swelling ratio of the 
GMHA-PEG-hexaglycine hydrogels (Figure 4.4). For gels with 4.4 µmol/ml 
hydrogel reactive sites and 0.4, 0.7, and 1.5 molar ratios of hexaglycine to 
hydrogel reactive sites, the swelling ratios were 35.9 ± 4.1 (n = 2), 29.6 ± 5.8 (n = 
3), and 27.6 ± 3.4 (n = 3), respectively. Gels with 15.7 µmol/ml hydrogel reactive 
sites and 0.3, 0.6, and 1.2 molar ratios of hexaglycine to hydrogel reactive sites, 
had swelling ratios of 19.3 ± 1.7 (n = 2), 16.3 ± 0.1 (n = 2), and 17.8 ± 1.7 (n = 2), 
respectively. For gels with 19.8 µmol/ml hydrogel reactive sites and 0.3, 0.6, and 
1.3 molar ratios of hexaglycine to hydrogel reactive sites, the swelling ratios were 
16.2 ± 0.1 (n = 2), 14.9 ± 0.1 (n = 2), and 15.7 ± 0.9 (n = 2), respectively.  
When the total number of hydrogel reactive sites was held constant and 
the moles of hexaglycine put into reaction were increased, the differences in 
swelling ratios were not statistically different. However, the swelling ratios for 
hydrogels with 4.4 µmol/ml reactive sites were statistically greater than those for 
hydrogels with either 15.7 or 19.8 µmol/ml reactive sites. Also, the difference in 
swelling ratios for the hydrogels with 15.7 µmol/ml reactive sites was not 
statistically different from those for the hydrogels with 19.8 µmol/ml reactive 
sites. 
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Figure 4.5 Degradation rate of GMHA-PEG hydrogels.  
GMHA degrades in the presence of hyaluronidase, but PEG does not. Therefore, 
we sought to determine the minimum concentration of 4-arm PEG required that 
would render the hydrogels essentially non-degradable by hyaluronidase. 
Hydrogels with 1.0 µmol/ml 4-arm PEG reactive sites are degradable, while gels 
with 2.3 µmol/ml 4-arm PEG reactive sites are not degradable. These data suggest 
the GMHA-PEG hydrogels are degradable by hyaluronidase when acrylated 4-
arm PEG contributes less than 50% of the total number of photoreactive groups. 
GMHA-PEG hydrogels in the presence of 5 U/ml hyaluronidase, ○; GMHA-PEG 
hydrogels in the presence of citric acid buffer alone, ▲. Each point represents the 
average ± standard deviation. 
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4.3.4 In Vitro Degradation by Hyaluronidase 
In vitro degradation rates (Figure 4.5) of the GMHA-PEG hydrogels were 
determined by incubating the gels in 5 U/ml hyaluronidase and monitoring the 
hydrogel masses over time. GMHA degrades in the presence of hyaluronidase [4], 
but PEG does not. Thus, we determined the maximum concentration of acrylated 
4-arm PEG beyond which the hydrogels are no longer degradable by 
hyaluronidase. The degradation rates for GMHA hydrogels (7.12 ± 1.80 %/hr, n = 
4) and GMHA-PEG hydrogels with 1.0 µmol/ml reactive sites contributed by 4-
arm PEG (3.76 ± 0.66 %/hr, n = 4) are statistically distinct and also greater than 
the degradation rates for the negative control (GMHA-PEG hydrogels incubated 
in citrate buffer alone; 0.98 ± 0.38 %/hr; n = 3) as well as the GMHA-PEG 
hydrogels with 2.3 µmol/ml or greater 4-arm PEG. However, hydrogels with 2.3 
µmol/ml (0.63 ± 0.15 %/hr; n = 4), 4.6 µmol/ml (0.83 ± 0.45 %/hr; n = 4), and 
17.5 µmol/ml (0.94 ± 0.08 %/hr; n = 2) were statistically indistinguishable from 
the negative control. These data indicate that the GMHA-PEG hydrogels are 
degradable by hyaluronidase when acrylated 4-arm PEG contributes less than 
50% of the total number of photoreactive groups. 
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Figure 4.6 Cell adhesion on GMHA-PEG-GRGDSG hydrogels.  
As a preliminary study of cell adhesion, normal human dermal fibroblasts were 
grown for 3 days on GMHA-PEG hydrogels alone (negative control), GMHA-
PEG-hexaglycine hydrogels (negative control) and GMHA-PEG-GRGDSG 
hydrogels. Cell adhesion in response to both the hexaglycine- and GRGDSG-
conjugated hydrogels was explored at peptide concentrations of 1.5 and 5 
µmol/ml. The number of fibroblasts adhering to hexaglycine-conjugated 
hydrogels is not statistically different from those adhering to GMHA-PEG 
hydrogels without peptide. The GMHA-PEG-GRGDSG hydrogels, however, 
were associated with significantly greater numbers of fibroblasts adhering to their 
surface than either the GMHA-PEG-hexaglycine composites or the GMHA-PEG 
hydrogels without peptide. Each bar represents the average plus the standard 
deviation.  
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4.3.5 Cell Adhesion 
 To preliminarily investigate the ability of the GMHA-PEG-peptide 
composite hydrogels to support cell adhesion, we incubated normal human dermal 
fibroblasts on the gels for 3 days (Figure 4.6). We focused on three types of 
hydrogels: GMHA-PEG hydrogels (a non-peptide negative control), GMHA-
PEG-hexaglycine conjugates (a non-bioactive peptide negative control) and 
GMHA-PEG-GRGDSG composites. Cell adhesion in response to both the 
hexaglycine- and GRGDSG-conjugated hydrogels was explored at peptide 
concentrations of 1.5 and 5 µmol/ml. The cells adhering on all GMHA-PEG 
hydrogels, regardless of the type of peptide, were fairly rounded in appearance. 
The number of fibroblasts adhering to the GMHA-PEG hydrogels (0.3 ± 0.5 
cells/mm2) was not statistically distinguishable from the number adhering to the 
GMHA-PEG hydrogels conjugated with either concentration of hexaglycine (1.5 
µmol/ml: 0.9 ± 1.5 cells/mm2; 5 µmol/ml: 2.0 ± 1.6 cells/mm2). The GMHA-
PEG-GRGDSG hydrogels, however, were associated with statistically greater 
numbers of adherent fibroblasts (1.5 µmol/ml: 7.9 ± 1.3 cells/mm2; 5 µmol/ml: 
8.6 ± 0.7 cells/mm2).  
4.4 DISCUSSION 
The specific goals of the work presented in this chapter were to modify 
glycidyl methacrylate-HA (GMHA) hydrogels with peptide sequences and to 
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determine the effects of the peptide conjugation on the hydrogels' 
physicochemical properties. To conjugate peptides onto GMHA, we investigated 
three complementary techniques: an EDC-mediated reaction on uncrosslinked 
GMHA and two photoactivated conjugations that take place during the 
crosslinking reaction. The three approaches are depicted schematically in Figure 
4.1. To conserve cost in each case, the conjugation chemistries were carried out 
with a model peptide, hexaglycine, and the process was optimized to maximize 
conjugation efficiency. We specifically chose hexaglycine for its simple chemical 
structure, as we intended for optimization with this peptide to serve as a stepping-
stone to conjugations with more functional peptides (e.g., RGD). 
 First, we investigated an EDC-mediated reaction between the carboxylates 
of uncrosslinked GMHA and hexaglycine's primary amine (Figure 4.2). This 
seemed to be a sensible approach as EDC-mediated reactions are commonly used 
for conjugating carboxylates and amines [15]. However, EDC reactions are highly 
dependent on pH, and an excess of amine is required for high levels of 
modification [10,15]. Furthermore, EDC-mediated reactions with HA have been 
found to be particularly challenging, as they readily convert HA's carboxylate to 
an unreactive N-acylurea [10,16,17]. We examined a variety of reaction 
conditions (pH, type of ester-activating agent, and concentrations of EDC, ester-
activating agent, and peptide) and found that the EDC-mediated GMHA-peptide 
conjugations resulted in efficiencies of less than 10%. As this low efficiency is in 
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agreement with other published HA studies [10,16,17], we chose to focus our 
attention on other conjugation techniques. 
 Next, we investigated two methods of incorporating peptides during the 
hydrogel photocrosslinking process. We hypothesized that a photoactivated 
reaction would allow higher conjugation frequencies as long as there are 
sufficient numbers of methacrylate or acrylate groups available for crosslinking as 
well as conjugation with acrylated PEG-peptides. Therefore, we sought to develop 
a chemistry that would yield solid hydrogels with conjugated peptide yields in the 
range of 1-5 µmol/ml. This range of peptide densities is based on those found to 
be optimal for cell adhesion and migration in non-adhesive PEG hydrogel systems 
[7,13,14].  
In Scheme I, acrylated PEG-peptides were mixed in a GMHA solution 
with a photoinitiator (Irgacure 2959) and a reaction accelerant (N-vinyl 
pyrrolidinone), and exposed to UV light. The acrylated PEG-peptides are 
incorporated into the hydrogel as the GMHA chains crosslink together. However, 
the solutions did not form stable hydrogels, possibly because there was an 
insufficient number of GMHA methacrylates available to contribute to both 
crosslinking and peptide modification.  
In Scheme II, we supplemented the total number of available 
photoreactive reactive sites by adding acrylated 4-arm PEG to the Scheme I 
gelation solutions. By varying the concentrations of acrylated 4-arm PEG and 
 124
acrylated PEG-peptides, we were able to synthesize hydrogels with a range of 
conjugation efficiencies, yields, swelling ratios, and enzymatic degradation rates.  
To establish a working range of reactant concentrations, we first focused 
on conjugation efficiency (Figure 4.3a,b) and yield (i.e., the peptide 
concentration in the hydrogel; Figure 4.3c,d). We expected that for a constant 
peptide input concentration, greater numbers of hydrogel reaction sites available 
would allow higher conjugation efficiencies. But, while the Scheme II reactions 
more readily formed solid hydrogel-peptide conjugates than the Scheme I 
reactions, increased acrylated 4-arm PEG concentration did not always allow 
higher conjugation efficiencies. We hypothesize that in these cases, the peptide 
conjugation reaction could have been limited by diffusion because efficiency 
decreased as the gelation solutions become more concentrated. Regardless, the 
Scheme II GMHA-PEG-peptide composites had much higher conjugation 
efficiencies (20-80%, versus less than 10% for the EDC-mediated reactions) and 
resulted in solid hydrogels with yields within the target range of 1-5 µmol/ml. 
In addition to peptide density, the hydrogel molecular structure can greatly 
impact cellular behavior [14,18,19]. Therefore, we measured the hydrogel 
swelling ratios (Figure 4.4) to determine the effect of varying acrylated 4-arm 
PEG and acrylated PEG-peptide concentrations. For a constant number of 
hydrogel reactive sites, increasing the concentration of acrylated PEG-peptide 
does not have a significant effect on swelling ratio. However, the hydrogels with 
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the lowest number of reactive sites (4.4 µmol/ml) have statistically greater 
swelling ratios than the hydrogels with greater moles of hydrogel reactive sites. 
This makes sense because fewer reactive sites will result in a lower crosslink 
density, which will be reflected by a relatively higher swelling ratio. 
We also explored cell adhesion on GMHA-PEG-peptide hydrogels with 
human fibroblasts (Figure 4.6), a common model for studying cell adhesion in 
vitro [5,6,13]. The GMHA-PEG hydrogels conjugated with the adhesive peptide 
sequence GRGDSG supported increased levels of cell adhesion compared to both 
of the negative control hydrogels. Although the concentrations of GRGDSG used 
in these studies are similar to the levels used in other investigations of cell 
adhesion on PEG hydrogels [7,13,14], the fibroblasts adhered to the GMHA-
PEG-GRGDSG hydrogels were not fully spread. However, hydrogel compliance 
can greatly affect cell activity [18], and because the stiffness of GMHA hydrogels 
[4] is much lower than hydrogels containing low molecular weight PEG [5], we 
hypothesize that the compliance of the GMHA-PEG hydrogels could be a limiting 
factor to cell adhesion. Nevertheless, we believe that the increased fibroblast 
adhesion on the GMHA-PEG-GRGDSG hydrogels compared to the adhesion on 
GMHA-PEG and GMHA-PEG-hexaglycine hydrogels are promising indications 
of the potential of these HA-based biomaterials. Thus, work ongoing in our 
laboratory will explore the possible effect of GMHA-PEG hydrogel stiffness on 
cell adhesion.  
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In conclusion, we report a simple method to conjugate adhesive peptide 
sequences to photocrosslinkable GMHA polymers. The properties of the GMHA-
PEG-peptide composites can be tuned by varying acrylated 4-arm PEG and 
acrylated PEG-peptide concentration. We created solid hydrogels with high 
conjugation efficiencies and tunable peptide yields, as well as controllable 
swelling ratios and degradation rates. Furthermore, the GMHA-PEG-GRGDSG 
composite hydrogels are able to support higher levels of fibroblast adhesion 
compared to GMHA-PEG hydrogels alone. We believe that these GMHA-PEG-
peptide composites provide a promising foundation for further modification and 
use in specific soft tissue engineering scaffolding applications. 
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Chapter 5: GMHA-PEG Hydrogels for Protein Delivery 
As discussed in Chapter 3, we have created photocrosslinkable glycidyl 
methacrylate-HA (GMHA) hydrogel tissue engineering scaffolds that are 
cytocompatible, biologically active, and resistant to enzymatic degradation by 
hyaluronidase. The goal of the studies presented in this chapter was to 
characterize the release of a model protein, bovine serum albumin, from GMHA 
and GMHA-polyethylene glycol (PEG) hydrogels. Though BSA was released 
rapidly (>60% within 6 h), increased GMHA and PEG concentrations were 
correlated with decreased protein release rates. To lengthen the duration of 
release, poly(lactic-co-glycolic acid) (PLGA) microspheres containing 
encapsulated BSA were suspended within the hydrogel matrix. We found that this 
approach was suitable for extending the duration of BSA release to several weeks. 
These initial studies indicate that the GMHA and GMHA-PEG hydrogels and 
hydrogel-microsphere composites are tunable systems for delivering stable 
proteins in soft tissue engineering applications.  
5.1 INTRODUCTION 
The fields of tissue engineering and biopharmaceutics provide a number of 
complex opportunities for the design of new implant materials [1-5]. Each 
individual application relies on rationally designed scaffolds and devices that 
interact with living systems in a highly controlled manner. For these reasons, it is 
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likely that no one biomaterial will satisfy all of the design parameters in all 
applications.  
The specific focus of our work has been soft tissue engineering 
applications, such as peripheral nerve repair. Ideal implants for soft tissues are 
degradable, porous, highly permeable, able to maintain a desired shape, and 
capable to specifically modulate biological responses (e.g., through bioactive 
factors such as covalently bound adhesive peptides or the controlled release of 
growth factors). In previous work, we made the first steps towards meeting these 
aims by creating new hydrogel scaffolds from crosslinked hyaluronic acid (HA) 
[6,7]. In this study, we expanded the HA-based hydrogels to create composite 
materials that are degradable, permeable, firm and yet pliable, and slowly release 
a model protein. 
As described in Chapter 3, we have developed a new biomaterial, 
glycidyl methacrylate-modified HA (GMHA), which can be photocrosslinked to 
form a highly hydrated and degradable tissue engineering scaffold [6]. HA 
presents a unique combination of advantages for biomaterial formulations: it is a 
naturally derived, enzymatically degradable, non-immunogenic, non-adhesive, 
bioactive glycosaminoglycan that has been associated with several cellular 
processes, including angiogenesis, extracellular matrix homeostasis, and the 
regulation of inflammation [8]. The GMHA hydrogels were found to be 
enzymatically degradable, cytocompatible, and the degradation products of 
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GMHA retained a similar level of bioactivity as unmodified HA fragments. 
Further development of these GMHA hydrogels focused on methods to attach 
peptides (e.g., the fibronectin-derived cell adhesion sequence RGD or arg-gly-
asp) [7]. Such sequences could allow control over several adhesion-related 
cellular processes, including migration and proliferation [9-11]. 
In addition to peptide sequences, encapsulated proteins can selectively 
alter hydrogel biofunctionality. Researchers have reported controlled protein 
delivery using a variety of hydrogel materials, including degradable and non-
degradable forms of synthetic and naturally derived materials [12-19]. Many of 
these materials are able to deliver proteins over extended periods of time (days to 
weeks) because the diffusional properties of the hydrogels are under a fine level 
of control [20]. It is likely that if the release of bioactive proteins is diffusion-
limited, that the diffusion of other soluble factors from the implant surroundings 
is also restricted. Though this design is preferred for the delivery of therapeutic 
proteins such as insulin [21] or antigenic proteins for vaccination [22], it poses 
several drawbacks for tissue engineering applications. For example, a number of 
regenerative processes, such as the guided growth of axons during peripheral 
nerve regeneration, rely on the diffusion of soluble growth factors and cytokines 
from the surrounding tissue [23]. Furthermore, regeneration is a highly 
demanding metabolic process, and the unhindered diffusion of nutrients and 
metabolic waste is critical for optimal cellular growth.  
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Aside from hydrogels, most materials designed for controlled release 
devices (e.g., microspheres, soluble gels, films) have structural or degradation 
properties that are not suitable for soft tissue scaffolds (e.g., two-dimensional or 
particulate structure, long degradation rates, or very quick dissolution times). 
Despite these challenging criteria, we were encouraged by the promising results 
from other HA-based strategies for controlled delivery [24-31]. Thus, our aim was 
to investigate protein release from our GMHA hydrogels, which were previously 
designed for soft tissue applications. Given that the mesh size of GMHA 
hydrogels is relatively large [6], we expected that protein release from these 
materials would be rapid. However, some tissue engineering systems, such as 
peripheral nerve repair, require several weeks to months to fully regenerate [32]. 
Therefore, we also chose to investigate hydrogel-microsphere composite release 
devices. Ideally, this composite system would provide greater control over protein 
activity and stability compared to covalently linking proteins directly to the 
matrix [13] and also provide advantages over methods relying on fine-tuning the 
hydrogel structure and diffusivity (as described above).  
In this work, we incorporated a model protein, bovine serum albumin 
(BSA), into GMHA and GMHA-polyethylene glycol (PEG) hydrogels. The 
diffusional properties of BSA within the hydrogels were examined as well as the 
effect of the photocrosslinking chemistry on protein aggregation. To extend the 
duration of protein release, we also created hydrogel-microsphere composite 
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release systems by dispersing BSA-containing PLGA microspheres within the 
hydrogel solution prior to crosslinking. These preliminary studies suggest that 
GMHA-based hydrogels and hydrogel-microsphere composites are tunable 
systems for delivering stable proteins in soft tissue engineering applications.  
5.2 MATERIALS AND METHODS 
5.2.1 GMHA Modification and Hydrogel Photocrosslinking 
We synthesized GMHA conjugates using previously developed methods 
[6] (for a detailed protocol see Appendix 1). Briefly, we made GMHA with 11% 
methacrylation by reacting a 1% (w/v) solution of fermentation-derived HA (~2 x 
106 Da, Clear Solutions Biotech, Stony Brook, NY) in distilled water with 20-fold 
molar excess of glycidyl methacrylate in the presence of excess triethylamine and 
tetrabutyl ammonium bromide. The reaction was mixed overnight at room 
temperature and then for 1 h at 60°C. Finally, the GMHA was precipitated in 
acetone and dissolved in deionized water twice, and then lyophilized.  
To synthesize photocrosslinked hydrogels, we exposed a gelation solution 
of GMHA (1-2% w/v in phosphate-buffered saline) to UV light (365 nm, ~22 
mW/cm2, 1 min exposure) in the presence of the photoinitiator Irgacure 2959 (1% 
w/v, Ciba Specialty Chemicals, Basel, Switzerland) and N-vinyl pyrrolidinone 
(0.3% v/v). To create GMHA-PEG hydrogels, 0.2 - 1.8 % (w/v) acrylated 4-arm 
PEG (MW 10,000; SunBio, Walnut Creek, CA) was also added to the solution.  
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5.2.2 Hydrogel Protein Release 
 To characterize the release of a model protein from the GMHA and 
GMHA-PEG hydrogels, 2% (w/v) BSA was dissolved in the gelation solutions 
prior to crosslinking. We crosslinked 50 µl of gelation solution in 8-mm diameter, 
2-mm deep rubber perfusion chamber molds (Sigma-Aldrich, St. Louis, MO) and 
then the hydrogels were carefully transferred to empty 15-ml polypropylene 
tubes. Once all of the hydrogels were synthesized, 15 ml of 37°C phosphate 
buffered saline (PBS) with 0.1% methylparaben (a preservative) was added to 
each tube. The tubes were mixed end-over-end (~10 rpm) at 37°C. At specified 
sample collection times, 1 ml of solution was transferred to a siliconized 1.5 ml 
microfuge tube and the 15-ml tube was replenished with 1 ml fresh 37°C PBS. 
The protein content of each sample was analyzed with the Bio-Rad (Hercules, 
CA) protein assay using the microassay procedure. Triplicate hydrogels were 
analyzed in each trial and the experiment was carried out three times. The mass 
released at time i was calculated from equation 5.1 [28]: 
∑ −+= s1iii VCVCM     (5.1) 
where Ci is the concentration of protein in the release solution at time i, V is the 
total volume of release solution (15 ml) and Vs is the sample volume (1 ml). 
 The hydrogels used during the protein release experiments (8 mm 
diameter, ~1 mm thick) satisfy the infinite slab condition (length at least four 
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times that of the slab thickness) [33]. The volume of the release solutions was 
approximately 300 times the volume of the hydrogels, fitting Crank's assumptions 
for an infinite open system with near-zero concentration boundary conditions (at 
least 20-fold greater fluid volume than that of the release matrix) [34].  
5.2.3 Calculation of De 
 Using the protein release data, the effective protein diffusion coefficient 
(De) was analyzed according to established methods [20,34]. Protein-loaded 
GMHA and GMHA-PEG hydrogels are homogeneous matrix controlled-release 
systems, which can be described by the following form of Fick's law of diffusion 
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where c is the concentration of protein within the hydrogel, x and t are position 
and time of release, 2δ is the hydrogel of thickness, and co is the initial protein 
concentration in the hydrogel. For short release times (Mt/M∞ < 0.6), equation 5.2 
can be solved to give   
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where Mt is the mass of protein released at time t, M∞ is the mass released at time 
infinity, and Mt/M∞ is the fractional mass of released protein. Equation 5.3 can be 
further reduced by only using the first term (n = 1) of the summation series to 
give 
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Therefore, the fractional release of protein released should be proportional to the 
square root of release time. The concentrations of released proteins at time t and 
at the end of the experiment (approximation of time infinity) were used to 
calculate Mt/M∞, which was in turn used to calculate De using equation 5.4. 
5.2.4 Size Exclusion Chromatography 
 To explore the effect of UV exposure on protein stability (i.e., 
aggregation), we analyzed the released protein solutions using size exclusion 
chromatography [35-39]. A Shimadzu (Columbia, MD) HPLC system consisted 
of a LC-10AT vp pump, a SIL-10A autoinjector, an APD-MI10A vp diode array 
detector and a 7.8 × 300 mm Protein Pak 125 column (Waters, Milford, MA). The 
mobile phase was a pH 7.4, 50 mM phosphate buffer containing 0.3 M sodium 
chloride, the flow rate was 0.5 ml/min, the sample concentrations were 
approximately 5 mg/ml, and the sample volume was 15 µl. The eluent was 
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detected using absorbance at 214 nm. Triplicate measurements were made for 
each sample. The amount of soluble monomer and mulitmer aggregates were 
determined using Peakfit (Systat Software, Richmond, CA).  
5.2.5 Microsphere Synthesis 
 To extend the duration of protein release from the hydrogels, PLGA 
microspheres containing BSA were suspended in the gelation solution prior to 
photocrosslinking. This section describes the microsphere synthesis and the next 
section describes the microsphere-hydrogel protein release experiments. The 
BSA-PLGA microspheres were synthesized using spray freezing into liquid (SFL) 
[37,38] and solid-in-oil-in-oil (s/o/o) encapsulation technologies [39]. 
 To create the solid protein phase, BSA was micronized using SFL [37,38]. 
Briefly, a 5 mg/ml solution of BSA in deionized water was delivered at high 
pressure (5000 psi) through a 65 µm nozzle. The nozzle was submerged below the 
surface of 1 L of liquid nitrogen to minimize the exposure of the BSA solution to 
air during the micronization and freezing steps. The frozen BSA particles were 
then lyophilized and stored at -70°C prior to encapsulation.  
 A previously developed s/o/o technique was adapted to encapsulate 
micronized BSA in PLGA microspheres [39]. To create the solid phase, 145 mg 
of SFL-processed BSA was placed in a glass scintillation vial and 10 ml of 
acetonitrile was added to make a protein suspension. A 10% (w/v) suspension of 
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magnesium hydroxide was passed through a 25 µm sieve and added to the protein 
suspension to achieve a base:protein mass ratio of 3:5. The protein-base 
suspension was sonicated on ice using a Branson Sonifer 450 (Branson 
Ultrasonics, Danbury, CT) with a 102 converter and tip operated at a duty cycle of 
6 (~35 W) for 20 min in pulse mode (0.5 s on, 0.5 s off).  
To create the solid-in-oil phase, a 2.5 ml aliquot of the sonicated protein 
suspension was dispensed into a new scintillation vial. A solution of 50% 
Resomer RG502H PLGA (50:50 lactic acid:glycolic acid, Mw ~7800, Mn ~4500; 
Boehringer Ingelheim, Ingelheim, Germany) in acetonitrile was added to bring the 
theoretical protein load to 5%, and the suspension was sonicated (same settings as 
above) for 2 min to achieve mixing. Excess acetonitrile was evaporated by 
immersing the vial in a room temperature water bath and blowing dry nitrogen 
gas over the surface of the suspension until the final concentration of solids 
(protein, base, and polymer) was 50% (w/v). The vial was weighed periodically 
during the purge step to ensure an exact reduction, and the total time of 
evaporation was about 30 min. To counteract potential settling of protein 
particles, the reduced suspension was sonicated for 20 s prior to the next step.  
The microspheres were formed from the solid-in-oil phase by creating an 
emulsion in 9 ml of paraffin oil containing 0.5% Span 85. The emulsion was 
mixed and then added to 100 ml cottonseed oil containing 1% Span 85 for solvent 
extraction (acetonitrile is more miscible in cottonseed oil than paraffin oil). The 
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paraffin and cottonseed oils were mixed well, the container was sealed, and the 
microspheres hardened for 1 h with periodic agitation to counteract settling of the 
microspheres. The spheres were separated from the oil by passing through a steel 
mesh screen with a 25 µm cutoff, washed with hexanes, and lyophilized for 24 h. 
 To determine the mass of protein encapsulated in the PLGA microspheres, 
5-10 mg of microspheres were added to 1 ml of acetonitrile. The PLGA was 
allowed to dissolve for 5 h at 37 °C, and then the samples were centrifuged (1500 
g for 30 min) to pellet the protein precipitate. The supernatant was discarded and 
the protein was dissolved in 1 ml PBS containing 0.1% methylparaben. The 
protein concentration was determined using a bicinchoninic acid (BCA) 
microassay kit (BCA-1; Sigma-Aldrich). 
5.2.6 Hydrogel-Microsphere Composites 
To extend the duration of BSA release, hydrogel-microsphere composites 
were created. Hydrogels containing 1% (w/v) GMHA with and without 1.8% 
(w/v) acrylated 4-arm PEG were prepared with 2% BSA using three methods: (1) 
2% BSA was dissolved in the gelation solutions prior to crosslinking (no 
microspheres); (2) half of the BSA (1% w/v) was dissolved in the gelation 
solution and the other half was contributed by BSA-PLGA microspheres, and (3) 
2% BSA was provided by BSA-PLGA microspheres (no BSA in the hydrogel 
bulk). In the hydrogel-microsphere composites, the BSA-PLGA spheres were 
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suspended in the gelation solution prior to crosslinking. BSA release was 
determined as above. Fick's law of diffusion does not apply to this heterogeneous 
system; therefore, De was not determined for the composite hydrogels. 
5.2.7 Microscopy Analysis 
 The PLGA microspheres, alone and suspended in the hydrogel matrix, 
were examined using scanning electron microscopy (SEM) and light microscopy, 
respectively. For SEM analysis, dry microspheres were mounted on a metal stage 
using double-sided carbon tape. The mounted microspheres were sputter-coated 
with ~30 nm of chromium and imaged with a LEO (Thornwood, NY) 1530 
scanning electron microscope at 100 - 2000x magnification.  
 To image the density of the microspheres within the hydrogel matrix, 40 
mg of BSA-PLGA microspheres were suspended in 0.1 ml gelation solution and 
then crosslinked under UV light. Images were captured at 20x magnification 
under brightfield microscopy using an Olympus IX70 microscope (Melville, NY) 
and an Optronics Magnafire camera (Goleta, CA).  
5.2.8 Statistical Analysis 
We performed Student's t-tests to determine the statistical significance of 
the differences between results. A significance level of p < 0.05 was used as the 
cutoff. 
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Figure 5.1 Release profiles of BSA from GMHA and GMHA-PEG hydrogels.  
Hydrogels (50 µl; 8 mm diameter, ~1 mm thick) containing 2% w/w BSA, various 
concentrations of acrylated 4-arm PEG and (a) 1% w/w GMHA or (b) 2% GMHA were 
incubated at 37°C with mixing in 15 ml PBS with 0.1% methylparaben. Although each 
hydrogel released at least 60% of the BSA within 6 h, hydrogels with increased 
concentrations of GMHA and PEG were associated with slower release rates. Triplicate 
hydrogels were analyzed and each data point represents the average fractional release of 
BSA (Mt/M∞) at each time, t for one experimental trial. The standard deviations for all 
data points are less than 0.2 and are arbitrarily shown for the 1.8% PEG hydrogels to 
indicate a representative level of error for all samples.  
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Figure 5.2 Linear fits of the hydrogel release profiles at Mt/M∞ < 0.6.  
Hydrogels (50 µl; 8 mm diameter, ~1 mm thick) containing 2% w/w BSA, various 
concentrations of acrylated 4-arm PEG, and (a) 1% w/w GMHA or (b) 2% GMHA were 
incubated at 37°C with mixing in 15 ml PBS with 0.1% methylparaben. Triplicate 
hydrogels were analyzed in each trial and the experiment was repeated three times (total 
n = 9). Each data point represents the average ± standard deviation of the fractional 
release of BSA (Mt/M∞) at each time, t.  
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5.3 RESULTS 
5.3.1 Protein Release From GMHA Hydrogels and De Calculations 
 The release of BSA from GMHA-based hydrogels was determined 
through two experiments. In all cases, triplicate hydrogels of each type were 
examined. The goal of the first experiment was to determine the duration of 
protein release and the total mass that is released in this time period. Samples 
were taken for up to 1 week, at which time it was assumed that all of the protein 
had been released. The percent of original BSA mass that was released from the 
hydrogels was 53.2 ± 5.04% and did not correlate with the concentration of either 
GMHA or PEG. As shown in Figure 5.1, each hydrogel type released >60% of 
the BSA within 6 h. Notably, hydrogels with increased concentrations of GMHA 
and PEG were associated with slower release rates.  
 A second set of experiments was used to determine De. Because equations 
5.3 and 5.4 only apply for Mt/M∞ < 0.6, we focused on the first 6 h of release. 
Each trial was repeated three times (n = 9 for each hydrogel). For each trial and 
hydrogel type, the average Mt/M∞ was plotted versus the square root of release 
time (t1/2). Linear fits were calculated with Microsoft Excel (Redmond, WA); 
representative results are shown for one trial in Figure 5.2. The slopes from three 
trials were averaged and used to calculate De and the normalized diffusivity, 
De/Do (Table 5.1). The values of De ranged from 0.85 x 10-7 to 4.54 x 10-7 cm2/s 
and decreased with increasing concentrations of GMHA and PEG (Figure 5.3).  
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Table 5.1 De and De/Do of BSA in GMHA and GMHA-PEG hydrogels 
Weight % GMHA Weight % acrylated 4-arm PEG De x 107 (cm2/s) De/Do* 
1 0 4.54 ± 0.42 0.48 ± 0.04
1 0.2 3.38 ± 0.91 0.36 ± 0.10
1 0.6 2.25 ± 1.02 0.24 ± 0.11
1 1.8 1.43 ± 0.93 0.15 ± 0.10
2 0 3.75 ± 0.50 0.40 ± 0.05
2 0.2 2.34 ± 0.55 0.25 ± 0.06
2 0.6 1.88 ± 0.57 0.20 ± 0.06
2 1.8 0.85 ± 0.36 0.09 ± 0.04
*Do (infinite-dilution diffusion coefficient), BSA in water at 37°C: 9.14 x 10-7 cm2/s [40] 
 
 
 
 
Figure 5.3 Normalized effective diffusion coefficients for BSA in GMHA and 
GMHA-PEG hydrogels. 
Based on the linear fits in Figure 5.2 and equation 5.4, we calculated the effective 
diffusion coefficient (De) for each type of hydrogel. The normalized diffusivity (De/Do) 
was obtained by dividing De by the infinite-dilution diffusion coefficient of BSA in water 
(Do), which is 9.41 x 10-7 cm2/s at 37°C [40]. Each bar represents the mean plus the 
standard error of the mean. 
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Table 5.2. Effect of photopolymerization on the physical state of BSA following 
release from GMHA and GMHA-PEG hydrogels  
  % Monomer in Released Protein 
Weight % GMHA Weight % PEG  
1 0 93.3 ± 0.04 
1 1.8 93.9 ± 0.33 
2 0 91.4 ± 0.31 
2 1.8 91.7 ± 1.67 
   
BSA Standard 84.7 ± 2.4 
 
5.3.2 Analysis of the Physical State of the Released BSA   
Exposure to UV light and crosslinking agents could affect protein 
structure and stability [41]. Possible effects of this process include protein 
denaturation, aggregation, hydrolysis, and reaction with the crosslinking agents, 
all of which could decrease the activity of encapsulated proteins. Therefore, we 
preliminarily explored the effect of photopolymerization on the physical state of 
encapsulated BSA using size exclusion chromatography (Table 5.2).  
The molecular weight of the BSA in the release solutions was determined 
for a hydrogel sub-set (combinations of 1% and 2% GMHA and 0% and 1.8% 
PEG) and was compared to the original BSA in solution (i.e., a BSA standard). 
The BSA in each of the release solutions was >90% monomer (<10% oligomers), 
while the BSA standard contained 84.7 ± 2.4% monomer (15.3 ± 2.4% 
oligomers). Therefore, the released BSA was enriched with monomer compared 
to the original protein. Small fragments were not detected, which indicated that 
significant amounts of hydrolyzed BSA are not being released from the hydrogels.  
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Figure 5.4 Release of BSA from hydrogel-microsphere composite systems.  
Hydrogels (50 µl; 8 mm diameter, ~1 mm thick) containing 1% (w/v) GMHA alone 
(solid symbols) and with 1.8% (w/v) acrylated 4-arm PEG (open symbols), were prepared 
with 2% (w/v) BSA using three different methods: (1) as in earlier experiments, 2% BSA 
was dissolved in the gelation solutions prior to photocrosslinking (no microspheres; 
diamond symbols); (2) half of the BSA (1% w/v) was dissolved in the gelation solution 
and the other half was contributed by BSA-PLGA microspheres (square symbols), and 
(3) 2% BSA was provided by BSA-PLGA microspheres (triangle symbols). In the 
hydrogel-microsphere composites, the BSA-PLGA spheres were suspended in the 
gelation solution prior to photocrosslinking. Triplicate hydrogels were analyzed and each 
data point represents the average ± standard deviation of the fractional release of BSA 
(Mt/M∞) at each time, t.  
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5.3.3 BSA Release From Hydrogel-Microsphere Composite Systems 
 To extend the duration of BSA release from the GMHA and GMHA-PEG 
hydrogels, PLGA microspheres containing 5% (w/w) BSA were suspended within 
the gelation solution prior to photocrosslinking. We obtained the release profiles 
(Figure 5.4) for three types of hydrogels: (1) 2% (w/v) BSA dissolved in the 
hydrogels (no microspheres), (2) half of the BSA (1%) in the hydrogel and half 
(1%) contained in BSA-PLGA microspheres, and (3) 2% BSA provided by the 
BSA-PLGA microspheres (no BSA dissolved in the hydrogel). In each case, the 
original total amount of BSA in the hydrogel or hydrogel-microsphere composite 
was 2% (weight BSA per total volume of the hydrogel or hydrogel-microsphere 
composite). Upon gross inspection, the microspheres did not seem to impair the 
photocrosslinking process and the vast majority of the microspheres remained 
embedded within the hydrogels for the duration of the release experiment. 
However, the presence of microspheres during the crosslinking process could 
affect the hydrogel properties (e.g., degradation rate, crosslink density); further 
studies would be required to study these effects in detail. 
As expected, the hydrogels without microspheres released all of the 
embedded BSA within 6 h. For the hydrogel-microsphere composites where the 
entire amount of BSA is provided by the BSA-PLGA microspheres, ~5% of the 
embedded BSA is released in the first day and then 30-40% of the remaining 
encapsulated BSA is released within 4 weeks. For the middle case, where half of 
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the BSA is dissolved in the hydrogel and the other half is encapsulated in the 
BSA-PLGA microspheres, a rapid release of 30-40% of the BSA is released 
within the first day, and then 60-70% of the remaining BSA is released within 18 
days.  
5.3.4 Microscopy 
 SEM analysis (Figure 5.5a,b) verified that the average size of the BSA-
PLGA microspheres is ~10-25 µm in diameter and also showed that the surface of 
the microspheres is smooth and relatively non-porous. Light microscopy of the 
hydrogel-microsphere composites (Figure 5.5c) confirmed that the microspheres 
were dispersed throughout the thickness of the hydrogel.  
5.4 DISCUSSION 
The first goal of this work was to characterize the release of a model 
protein, BSA, from GMHA and GMHA-PEG hydrogel scaffolds. These materials 
have previously been shown to be photocrosslinkable, biocompatible, bioactive, 
enzymatically degradable, porous, and highly hydrated [6,7]. We found that the 
release rate of BSA from the hydrogels to be rapid (>60% release within 6 h; 
Figure 5.1). This was not surprising, as the mesh size of GMHA hydrogels has 
been estimated to be on the order of several hundred nm [7], which is much larger 
than the dimensions of BSA (approximately 4.2 nm in diameter and 14.4 nm long 
[42]).  
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Figure 5.5 Microscopy images of BSA-PLGA microspheres alone and embedded 
in a GMHA hydrogel.  
SEM images of dry sputter-coated BSA-PLGA microspheres were captured at (a) 300x 
magnification (scale bar, 100 µm) and (b) 2000x magnification (scale bar, 10 µm). (c) 
Light microscopy was used to image 40 mg/ml BSA-PLGA microspheres embedded in 
crosslinked GMHA hydrogel (scale bar, 100 µm). 
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Table 5.3: Comparison of De and De/Do of BSA released from GMHA and 
GMHA-PEG hydrogels with literature  
Matrix Solute Conditions De x 10
7 
(cm2/s) De/Do Reference 
GMHA hydrogels BSA 37°C, in PBS 0.85 - 4.54 0.09 - 
0.48 
See Table 
5.1 
Polyvinyl alcohol 
membranes 
BSA 37°C, in 
water 
0.18 - 8.07 0.02 - 
0.86 * 
[43] 
Polyacrylamide 
hydrogels 
BSA 37°C, in PBS ~0.5 - ~2 ~0.05 - 
~0.2 * 
[12] 
PEG-diacrylate  
(2000 Da) hydrogels 
BSA 37°C, in PBS 0.005 0.0005 [44] 
PEG-diacrylate  
(575 Da) hydrogels 
BSA 37°C, in PBS < 0.004 <0.0005 [16] 
GMHA-PHEA 
hydrogels 
Sodium 
benzoate 
25°C, in 
water 
1.2 - 69.5 0.01 -
0.632 
[28] 
Abbreviations: Effective diffusion coefficient (De), diffusion coefficient in water (Do), bovine 
serum albumin (BSA), glycidyl methacrylate (GM), hyaluronic acid (HA), phosphate buffered 
saline (PBS), polyethylene glycol (PEG), polyhydroxyethyl acrylate (PHEA) 
* De/Do was not reported in original references and were calculated from reported De and Do = 
9.41 x 10-7 cm2/s for BSA at 37°C [40] 
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An effective method of comparing the protein release from different 
hydrogel materials is to calculate the effective diffusion coefficient, De [20]. The 
values of De for BSA released from GMHA and GMHA-PEG hydrogels ranged 
from 0.85 x 10-7 - 4.54 x 10-7 cm2/s, which is within the range that is typically 
found for diffusion through rubbery polymers [20]. We found that there is a 
significant decrease in De for these systems compared to the infinite-dilution 
diffusion coefficient, Do, for BSA in water at the same temperature (Table 5.1).  
Hydrogels with decreased hydrogel water content (increased concentrations of 
GMHA or PEG) were associated with lower values of De (Figure 5.3), in 
agreement with published work with other release systems [45]. Furthermore, the 
De/Do values are also in general agreement with other similar release systems 
(examples summarized in Table 5.3). Notable exceptions are the remarkably low 
De/Do values obtained for non-degradable low molecular weight PEG hydrogels 
[16,44]. These highly crosslinked hydrogels are ideal for the delivery of 
biopharmaceutic proteins; for soft tissue engineering applications, however, such 
materials could be associated with potential drawbacks (e.g., non-degradable, 
highly crosslinked structure that impedes the diffusion cellular nutrients, 
endogenous signaling molecules, and metabolic waste). 
As the GMHA hydrogels are crosslinked in the presence of BSA, we were 
interested in determining whether the crosslinking agents or the exposure to UV 
light affects protein stability. We carried out preliminary studies to evaluate the 
presence of BSA aggregates in the release solutions using size exclusion 
chromatography. We found that the release solutions were, in fact, enriched in the 
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monomer form of BSA compared to the BSA standards (Table 5.2). Additionally, 
only about 53% of the BSA in the uncrosslinked gelation solutions is released 
from the hydrogels. We hypothesize that the hydrogels may selectively allow the 
release of the lower molecular weight monomer, while larger aggregates are 
retained. Similar effects have also been noted for PLGA microspheres [36]. 
However, these data do not preclude the fact that the BSA could be bound to the 
hydrogel matrix via reaction with the crosslinking reagents, free radical addition, 
or a Michael-type addition between lysine amino acids in the protein and acrylate 
or methacrylate groups in the polymers [16]. The BSA also could have 
nonspecifically adsorbed to the release vial surfaces or formed complexes with 
HA [46] or PEG [47]. Further investigation of the BSA structure within the 
hydrogel, using a technique such as fourier-transform infrared spectrometry 
(FTIR) [16,38], may help to clarify this issue.  
The second goal of this work was to extend the duration of protein release 
from the GMHA hydrogels. We were particularly interested in methods that 
preserve the native protein structure and also provide a versatile method of fine-
tuning the protein release rate. The simplest method of extending protein release 
is to decrease the diffusivity of the materials by decreasing the hydrophilicity [48] 
or diffusivity [45] of the hydrogel structure. Covalently linking the protein to the 
hydrogel matrix is another method to slow down protein delivery [13]. Each of 
these methods has been applied towards modifying HA for drug delivery 
applications [31], but as mentioned earlier, these methods pose drawbacks for 
tissue engineering applications.  
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A composite hydrogel-microsphere system, on the other hand, poses 
significant advantages for the controlled release of therapeutic proteins from a 
three dimensional matrix. Foremost, sustained release from microspheres is one of 
the most extensively studied and clinically utilized systems for delivering one-
time injectable drugs or proteins [49]. Recent research focusing on protein 
delivery from microspheres has made great progress towards meeting this 
system's primary technical challenges: high protein stability and minimal rapid 
early release (i.e., "burst") [17,48]. In particular, work at The University of Texas 
at Austin by Drs. Keith P. Johnston and Robert O. Williams, III in the 
departments of Chemical Engineering and Pharmaceutics, have developed new 
methods for increasing the effectiveness of microencapsulated proteins. Two 
techniques in particular, a novel spray freezing into liquid (SFL) protein 
preparation [37,38] and an improved solid-in-oil-in-oil (s/o/o) microsphere 
synthesis have been used in conjunction to stabilize proteins with the virtual 
elimination of rapid early release [39]. These techniques circumvent air-water and 
water-organic interfaces, which have been linked to protein denaturation in other 
encapsulation techniques such as spray freeze drying of proteins [50] and the 
water-in-oil-in-water (w/o/o) double emulsion process [36,51,52]. 
To extend the duration of BSA release from the GMHA and GMHA-PEG 
hydrogels, BSA-PLGA microspheres were created with SFL-prepared BSA and 
the s/o/o encapsulation process. Magnesium hydroxide was also encapsulated in 
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the PLGA microspheres; this poorly water-soluble base has been demonstrated to 
prevent the acid denaturation associated with the acidic environment within 
degrading PLGA microspheres [53]. As expected, the BSA-PLGA microspheres 
extended the duration of release in a dose-dependent fashion (Figure 5.4). 
Hydrogel-microsphere composites with half of the BSA in the hydrogel and half 
in the PLGA microspheres were associated with a two phase release profile: a 
rapid release phase within the first day and an extended release phase lasting 
several weeks. Such a release profile may be advantageous for applications such 
as peripheral nerve regeneration that could benefit from an early release of anti-
inflammatory or angiogenic factors and an extended release of a neurotrophic 
factor such as nerve growth factor. 
In conclusion, we report a characterization of the protein release from 
GMHA and GMHA-PEG hydrogels as well as hydrogel-microsphere composite 
systems. The hydrogel release profiles were rapid, but could be controlled by 
varying the GMHA and PEG concentrations. Preliminary studies suggest that the 
BSA released from the hydrogel matrices is almost entirely released in the 
monomeric form, indicating that the photocrosslinking step does not contribute to 
high amounts of protein aggregation. However, more detailed studies will be 
required to confirm these results. Finally, BSA-PLGA microspheres synthesized 
using SFL-processed BSA and a non-aqueous s/o/o technique were shown to 
extend the duration of BSA release from hydrogel-microsphere composites to 
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several weeks. These initial studies indicate that these GMHA and GMHA-PEG 
hydrogels and hydrogel-microsphere composites are tunable systems for 
delivering stable proteins in soft tissue engineering applications. Future work will 
examine the effect of the microspheres on the hydrogel degradation and the in 
vitro cellular response to the microsphere-hydrogel composite systems releasing 
bioactive proteins, such as growth factors. 
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Chapter 6: Conclusions and Recommendations 
6.1 SUMMARY 
Ideally, rationally designed tissue engineering scaffolds should promote 
directed interactions with complex living systems. With this goal in mind, we 
sought to create a biomimetic hydrogel material to support the regeneration of soft 
tissues (e.g., peripheral nerve). Model implants for soft tissues should be 
degradable, porous, highly permeable, able to maintain a desired shape, and able 
to precisely modulate biological responses. Naturally derived materials are 
particularly suitable for these applications as they are degradable and intrinsically 
bioactive. Our work has made significant progress towards completing this aim 
through the design and characterization of crosslinked hyaluronic acid (HA) 
hydrogel scaffolds. 
The accomplishments of this dissertation were organized into three main 
areas: (1) the development of a novel hydrogel tissue engineering scaffold based 
on photocrosslinkable glycidyl methacrylate-modified HA (GMHA), (2) the 
enhancement of GMHA-based hydrogels by covalently binding bioactive peptide 
sequences to the hydrogel matrix, and (3) the characterization of GMHA-based 
hydrogels and hydrogel-microsphere composite materials for controlled protein 
release. In summary, this work provides a new and versatile tissue engineering 
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scaffold designed expressly for augmenting the repair and regeneration of soft 
tissue injuries.  
Future work, as outlined below, is recommended to further enhance these 
materials for specific soft tissue applications (e.g., nerve repair), to more 
thoroughly investigate the chemical and biological properties of GMHA and 
GMHA-based hydrogels, and to use the glycidyl methacrylate modification 
chemistry as a platform for the development of new naturally derived materials. 
6.2 RECOMMENDATIONS FOR FUTURE RESEARCH 
6.2.1 Development GMHA Hydrogels for Nerve Repair 
The original long-term goal of this work was to use crosslinked HA 
materials in the study of peripheral nerve repair. However, significant hurdles in 
the design of the HA-based hydrogels prevented us from immediately reaching 
this goal. These challenges have nevertheless uncovered several potential areas of 
exciting research. 
First, a more detailed understanding of the potential mechanisms for HA 
degradation in regenerating peripheral nerve is required. Currently, we do not 
know the local levels of hyaluronidase in nerve injury sites. Even less clear, is the 
availability of other means of HA degradation, such as oxygen free radicals. 
Without thorough knowledge about the kinetics of these processes it is 
exceedingly difficult to match the degradation rate of HA-based materials to the 
time scale of nerve regeneration.  
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Second, the organization and presentation of covalently bound peptides 
must be finely tuned to maximize the cellular responses required for directing the 
growth of axons. For instance, bioactive or adhesive peptide sequences could be 
used to support the infiltration of support cells (e.g., Schwann cells, endothelial 
cells) into the hydrogel scaffold. Cellular infiltration, however, is a process that 
relies not only on cellular adhesion and migration, but also degradation of the 
scaffolding material. This fact clearly emphasizes the importance of the first area 
of suggested research, understanding the HA-degradation mechanisms in nerve 
tissue. Fortunately, covalently bound peptide sequences could also be used for an 
additional mode of matrix degradation: proteolytically degradable crosslinks 
between the GMHA chains. Thus, covalently bound peptides could be used in 
several ways to further tune the biological properties of GMHA hydrogels. 
Third, the encapsulation and delivery of bioactive proteins must be more 
thoroughly developed for fragile proteins such as growth factors. BSA is a well-
established model for preliminarily characterizing protein delivery devices; 
however, it is also a relatively stable protein. Neurotrophic and angiogenic 
proteins (e.g., nerve growth factor and vascular endothelial growth factor) could 
add a potent mechanism for promoting nerve repair, but they are easily denatured 
and degraded by many techniques for materials synthesis. Therefore, in depth 
studies of the bioactivity and release rate of these growth factors are required 
before GMHA materials could be successfully applied for this use. 
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6.2.2 HA-Based Materials for Studying Biological Systems 
As discussed in Chapter 2, HA is involved in a number of biological 
processes. However, the exact mechanisms by which it influences cellular 
behavior are not clear. Designing new functionalized forms of HA may provide a 
unique engineering approach for studying these systems. For example, many 
facets of HA's biological activity could be studied by progressively masking the 
carboxyl, hydroxyl, and acetamido functional groups in HA's backbone. Such 
changes would consequently affect receptor recognition sites or the 
physicochemical properties of the polymer (e.g., hydrophilicity, stiffness). 
Furthermore, the methods presented in this work could be used as a springboard 
for the development of new HA functionalization chemistries. For instance, by 
tagging HA with fluorescent molecules, one may conduct detailed studies of in 
vivo HA degradation or cellular processes such as receptor-mediated endocytosis.  
6.2.3 Novel Naturally Derived Materials  
One key advantage to the glycidyl methacrylate modification technique 
described in these studies is that one could apply the same chemistry to other 
glycosaminoglycans, including heparan sulfate, chondroitin sulfate, and dermatan 
sulfate. The biological activity and function of glycosaminoglycans are current 
areas of active research. It is likely that these robust bioactive polymers are also 
suitable foundations for hydrogel biomaterials. 
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A.1 GLYCIDYL METHACRYLATE-HYALURONIC ACID (GMHA) HYDROGELS 
 
 This protocol presents a two-step process for making crosslinked hyaluronic acid 
(HA) hydrogels. The first step is the modification of HA with glycidyl methacrylate 
(GM) to yield GMHA; the second step is photocrosslinking under UV light. 
 Published in Biotechnol Bioeng 82:578-89 (2003) 
 See also similar chemistries using GM and methacrylic anhydride (references below). 
 
GMHA Conjugate Polymers 
 
Materials 
Hyaluronic acid       Collaborative Labs 
Glycidyl methacrylate*       Aldrich 151238 
Triethylamine*        Aldrich 471283 
Tetrabutyl ammonium bromide      Fluka 86860  
Acetone*  
Glass bottles with lids or Ehrlenmeyer flasks with stoppers     
Assorted beakers  
Glass rods or pipets   
 
* Hazardous component—be sure to read MSDS before use. Wear safety goggles, nitrile gloves 
and a lab coat.  
 
Procedure for 5% Methacrylated GMHA (4-7 days depending on batch size) 
1. Dissolve 0.5g HA in 50 ml dI on a stir plate in a chemical fume hood. Thorough 
dissolution can take several hours to overnight. 
2. Add the following components separately and in the following order: 1.0 ml 
triethylamine, 1.0 ml glycidyl methacrylate, 1.0 g tetrabutyl ammonium bromide. 
Thoroughly mix before adding the next component. 
3. Mix at room temperature in a sealed flask in a chemical fume hood overnight. 
4. Incubate the reaction at 50-60°C for 1 h (open the flask seal slightly) and cool to 
room temperature. 
5. Precipitate in acetone, using one part HA solution to 20 parts acetone.  
 Pour acetone into a 1L beaker and while stirring with a glass rod or pipet, slowly 
add the HA solution.  
 The GMHA will precipitate as a cottony white solid that should collect on the 
glass stirrer. 
 If the acetone starts getting cloudy and precipitation stops, start again with fresh 
acetone. 
6. Transfer the precipitate to a small glass dish and rinse with fresh acetone. 
7. Thoroughly dissolve the precipitate in about 30 ml dI (can take several hours, but 
should dissolve faster than unmodified HA). 
8. Repeat steps 5-7 to remove all residual excess reactants. 
9. Lyophilize frozen solution 24-48 hours and store with desiccant at –20 or 4°C. 
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7% methacrylated GMHA 
Follow the procedure for 5% methacrylated GMHA, except add 1.8 ml triethylamine, 1.8 
ml glycidyl methacrylate, and 1.8 g tetrabutyl ammonium bromide to the reaction. 
 
11% methacrylated GMHA 
Follow the procedure for 5% methacrylated GMHA, except add 3.6 ml triethylamine, 3.6 
ml glycidyl methacrylate, and 3.6 g tetrabutyl ammonium bromide to the reaction. 
 
1NMR Analysis of Methacrylation 
 
Materials 
Deuterated water (D2O) 
NMR tubes 
 
To verify the extent of methacrylation: make a 0.5% solution of GMHA with D2O and 
submit for 1H-NMR. Compare the peak heights per proton of the HA methyl peaks (at 
1.82 or 1.93) and methacrylate peaks (at 5.55 and 5.24). 
 
Crosslinking 
 
Materials 
GMHA 
Phosphate buffered saline (PBS) 
Irgacure 2959 (2959)     Ciba Specialty Chemicals 
N-vinyl pyrrolidone (VP)*     Aldrich V340-9  
UV lamp (365 nm long wave)^    Blak-Ray Model B-100A 
 
* Hazardous component—be sure to read MSDS before use.  
^ When using the UV light, use eye protection and minimize direct exposure to skin. 
 
 VP acts as a reaction accelerant and co-monomer.  
 Although VP concentrations up to 3% produce more highly crosslinked gels with 
shorter UV exposures, concentrations above 0.5% have been shown to be cytotoxic. 
Similarly, concentrations of 2959 above 0.1% have been shown to be cytotoxic to 
photoencapsulated chondrocytes (J Biomater Sci Polym Ed 2000, 11: 439) 
 The first procedure below outlines 1-3% VP gels, which may have interesting 
material properties; the second procedure outlines a less cytotoxic procedure with 
<0.3% VP and PBS as the 2959 solvent. 
 Minimize the exposure of 2959 solutions to ambient light. 
 Solutions of up to 1.5% GMHA can be sterile filtered through a 0.2 µm pore size 
syringe filter with a 0.8 µm pore size prefilter (0.8/0.2 µm Pall Gelman Supor 
Acrodisc PF syringe filter). 
 
1-3% VP Gels 
1. Make a 0.5-2.0% solution of GMHA in PBS and dissolve thoroughly overnight. 
2. Dissolve 2959 in VP at 250 mg/ml. Store in the dark at R/T up to 1 month. 
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3. Add the 2959 solution** to the GMHA solution and mix well.  
4. Expose the solution (up to 1-cm thick) to UV light 0.5-4 minutes** to produce a 
solid gel. 
 
<0.3% VP Gels 
1. Make a 1% 2959 solution in PBS. To dissolve, sonicate the solution and heat to 
50°C until the 2959 is completely dissolved. Add 0.3% VP in a chemical fume 
hood. Store at R/T in the dark up to 1 month. 
2. Make a 0.5-2.0% GMHA solution in 2959/PBS/VP solution**; allow to dissolve 
thoroughly in the dark. 
3. Expose the solution (up to 1-cm thick) to UV light 0.5-4 minutes** to produce a 
solid gel. 
 
** The amount of 2959, VP, and UV exposure needed should be determined experimentally 
and depends on the GMHA degree of methacrylation. 
 
Variables to Achieve Varying Degrees of Crosslinking 
 
 Degree of methacrylation         
 Molar excess GM, triethylamine, tetrabutyl ammonium bromide in reaction 
 Reaction temperature 
 Length of reaction  
 
Crosslinking 
 Concentration of 2959, VP, GMHA 
 Intensity or time of UV exposure 
 Addition of other components (e.g., acrylated PEG) 
 
Additional references on similar chemistries 
 
Glycidyl Methacrylate 
Jin, et al. J Control Release 73: 173-81 (2001). 
Trudel & Massia. Biomaterials 23: 3299-3307 (2002). 
Park, et al. Biomaterials 24:578-89 (2003). 
 
Methacrylic Anhydride 
Smeds, et al. J.M.S.—Pure Appl. Chem. A36(7&8): 981-9 (1999). 
Smeds & Grinstaff. JBMR 54:115-21 (2001). 
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A.2 SWELLING ASSAY WITH TGA 
 
 To assess the hydrogels' degree of swelling, the equilibrium weight-swelling ratio, q, 
is determined. This ratio is found from the swollen gel weight (Ws) divided by the 
dry gel weight (Wd).  
 The swelling ratios are measured using a Perkin-Elmer TGA-7 Thermogravimetric 
Analyzer (TGA).  
 The calculated swelling ratio will allow a relative comparison of different gel 
chemistries. Increased crosslinking will allow less swelling, thus a lower swelling 
ratio, than a gel with relatively less crosslinking. 
 
Materials 
 
Hydrogel samples 
Phosphate buffered saline (PBS) 
TGA equipment 
 
Procedure 
 
1. Swell the hydrogel samples overnight in PBS. 
2. Start the TGA equipment.  
3. During the run, it is necessary to determine Ws (initial swollen weight at room 
temperature) as well as Wd. The gel starts to decompose above about 115°C. Setup a 
profile similar to the following: 
 25-100°C ramp at 20-35°/minute 
 100°C for 5-20 minutes 
4. Cut the hydrogel sample into 8-20 mg pieces. Keep the pieces wet until testing. 
5. Run the TGA profile. 
6. Record the entire weight vs. temperature or only the initial weight and the plateau 
weight at about 100°C. 
7. Calculate the swelling ratio by dividing the swollen gel weight by the dry weight. 
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A.3 HYDROGEL DEGRADATION STUDIES 
 
Hydrogel degradation studies are used to determine the relative extent of gel crosslinking 
due to the differences in their degradation rate in hyaluronidase (hyase) solutions. 
 
Materials 
 
GMHA gelation solution 
Coverwell perfusion chamber molds    Sigma Z379220 
Microscope slides 
No. 1 coverslips (optional) 
Teflon-coated coverslip foreceps 
24-well plate 
Bovine testicular hyaluronidase (hyase)    Sigma H3506 
Citrate buffer (see below) 
 
Procedure 
 
1. Tear off the plastic films from both sides of the perfusion chambers. Clean off any 
residual adhesive with ethanol. Stick the smooth side to a microscope slide. Look at 
the underside of the slide to make sure that the mold is thoroughly adhered.  
2. Crosslink 0.1 ml gels in the perfusion chamber molds. Peel off the perfusion chamber 
mold. Using a coverslip or coverslip foreceps, carefully remove the gels from the 
slide and transfer to individual wells in a 24-well plate.  
3. Soak in 0.5-1.0 ml citrate buffer overnight at R/T to allow equilibrium swelling. 
4. Carefully remove the citrate buffer while trying not to disturb the gel. Remove the gel 
with the coverslip foreceps and carefully blot to remove excess liquid. Weigh the gels 
individually to obtain their initial weights. A small weigh boat turned upside-down 
makes a good platform that can be dried off between measurements. 
5. Make a fresh batch of hyase (5-500 u/ml) in citrate buffer. Add 0.5-1.0 ml hyase 
solution to each well and incubate at 37°C on a shaker. 
6. At desired time points, remove the hyase solution, carefully weigh the gel and return 
to the 24-well plate. Add fresh hyase solution and return to incubator. If gels have a 
very low extent of crosslinking and are very weak, use one gel per time-point.  
7. Plot percent degradation versus degradation time. The initial linear slope is the 
'degradation rate' in percent weight loss per time. 
 
Citrate buffer, pH 5.3 
 
  4.393 g 1.757  g  NaCl 
20.113 g 8.045  g  Na2HPO47H2O 
  2.883 g       1.153  g  citric acid 
500 ml   200     ml Deionized water   
 
Adjust pH to 5.3.  Filter sterilize, if necessary. 
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A.4 HYDROGEL HAEC CYTOCOMPATIBILITY ASSAY 
 
 This is an in vitro method for determining hydrogel compatibility with living cells. 
The cells are incubated in indirect contact with the hydrogel, a method adapted from 
published work (Biomaterials 2002 23:3299-3307) 
 The Promega CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay is a 
colorimetric method for determining the number of viable cells in proliferation or 
toxicity studies. It is a safer and simpler version of the popular MTT cell assay. In the 
CellTiter assay, MTS is bioreduced by cells into a formazan that absorbs at 490nm. 
 
Materials 
 
GMHA gelation solutions 
0.8/0.2 µm Pall Gelman Supor Acrodisc PF syringe filter VWR 28144-009 
>3 ml syringes 
Corning Costar Transwell inserts (6.5 mm, 0.4 µm pore size) Fisher 07-200-147 
Sterile 24-well TC plate 
Phosphate buffered saline (PBS) 
General tissue culture supplies 
Human aortic endothelial cells (HAECs)*   Clonetics CC2535 
Endothelial Growth Medium-2 (EGM-2)   Clonetics CC3162 
CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay  Promega G5421 
 
* Be sure to obtain biohazard safety training before handling human cells. 
 
Methods 
 
1. Sterile filter the GMHA gelation solutions using the Acrodisc syringe filter and a >3 
ml syringe. 
2. In a sterile field, crosslink 0.1 ml gels in individual Transwell inserts. 
3. Wash the hydrogels for 5 minutes each in PBS and then EGM-2. 
4. Seed HAECs in the 24-well plate at a density of 6250 cells in 1 ml EGM-2 per well. 
5. After the cells have adhered (at least 30 minutes of incubation) add the Transwell 
inserts containing the hydrogels to the wells. 
6. After 24 hours of incubation, determine the cell viabilities using the CellTiter 
proliferation assay according to the manufacturer's instructions. 
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A.5 HAEC PROLIFERATION ASSAY  
 
 This protocol uses the Promega CellTiter 96 Aqueous Non-Radioactive Cell 
Proliferation Assay, which is a colorimetric method for determining the number of 
viable cells in proliferation or toxicity studies. It is a safer and simpler version of the 
popular MTT cell assay. MTS is bioreduced by cells into a formazan that is visible 
and absorbs at 490nm. 
 This assay uses human aortic endothelial cells (HAECs), but can be adapted for use 
with other cell types; see the CellTiter instructions for details. 
 
Materials  
 
Experimental and control doses (sterile) 
Phosphate buffered saline (PBS) 
General tissue culture supplies 
Human aortic endothelial cells (HAECs)*   Clonetics CC2535 
Endothelial Growth Medium-2 (EGM-2)   Clonetics CC3162 
Endothelial Basal Medium-2 (EBM-2)    Clonetics CC3156 
Heat-inactivated fetal bovine serum (FBS)   Hyclone SH30071.03 
96-well plate 
Multi-channel pipetman 
CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay  Promega G5421 
 
Methods 
 
1. Seed the wells of a 96-well plate with 10,000 HAECs per well in EGM-2. 
2. After the cells have adhered (2-4 hours), starve the cells overnight in EBM-2 with 1% 
heat-inactivated FBS ("starvation medium"). 
3. The next day, dose with experimental and control doses, 0.2 - 0.3 ml/well, 3-4 wells 
per dose, diluted in starvation medium. Suitable positive and negative controls are 
EGM-2 and starvation medium, respectively.  
4. After 48-72 hours of incubation, remove all but 100 µl of liquid from the wells. Add 
20µl of the CellTiter MTS/PMS solution per well. Return the plate to the incubator. 
5. After 1, 2, 3, 4 hours, measure the absorbance of the wells at 490 nm with a plate 
reader. The absorbance of the wells is proportional to numbers of viable cells. 
Typically, the most reliable results are obtained at the 3 hour time-point, but this 
should be re-determined if cell type or density is changed. 
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A.6 CD31 IMMUNOHISTOCHEMICAL STAIN FOR TISSUE CRYOSECTIONS 
 
 CD31 is an endothelial cell specific marker 
 This protocol is optimized for frozen cryosections and is not recommended for 
paraffin embedded tissues. 
 Protocol adapted from Tim King, Eric Brey, and Charles Patrick at The University of 
Texas M.D. Anderson Cancer Research Center (Houston, TX) 
 
Materials 
 
Mouse anti-rat CD31 primary antibody   Serotec  MCA1334G 
Goat anti-mouse IgG secondary antibody conjugated with horseradish peroxidase (HRP) 
       Serotec STAR77 
3,3-diaminobenzidinetetrahydrochloride (DAB)  Research Genetics 750118 
Phosphate buffered saline (PBS) 
Horse serum      Sigma H0164 
Goat serum      Sigma G6767 
Methanol*       
30% hydrogen peroxide (H2O2)* 
Acetone* 
Brij detergent      Fisher BP345-500 
Gill's #3 hematoxylin*     Sigma GHS-3-16 
Universal Mount     Research Genetics 750105 
PAP pen or rubber cement 
 
* Hazardous materials – be sure to read MSDS sheets and wear protective equipment 
 
Brij solution: Add 20 µl Brij detergent to 50 ml distilled water. Adjust pH to 7.6. 
 
Protein blocking solution: Freshly prepared 5% normal horse serum with 1% normal goat 
serum in PBS: 
 
   50 ml  25 ml  12.5 ml 
 Goat:    0.5 ml    0.25 ml   0.125 ml 
 Horse:    2.5 ml    1.25 ml   0.625 ml 
 PBS:  47.0 ml  23.5   ml 11.75 ml 
 
Endogenous peroxidases: Freshly prepared (no more than 20 min old at time of use) 3% 
H2O2 in methanol 
1 ml 30% H2O2 in 9 ml methanol 
5 ml per 20 slides 
 
Antibody solutions: Made in protein blocking solution at recommended concentration. 
Prepare about 50-70 µl per section. 
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Method 
 
All incubations should be performed in a humidity chamber and do not allow the sections 
to dry out.  
 
Day one (approx 2-2.5 hr) 
 
1. Fix slides in -20°C acetone for 5 min. 
2. Rinse slides in PBS (3x for 3 min each). 
3. Remove slides one at a time, wipe off excess PBS and circle tissue with a PAP pen or 
a thin band of rubber cement dispensed from a syringe (without needle). 
4. Place slides in humidity chamber. 
5. Block endogenous peroxidase by incubating with 3% H2O2 in methanol for 12 min. 
Add a second drop of solution at 6 min. 
6. Rinse with PBS (3x for 3 min each). 
7. Incubate with protein blocking solution for 20 min. 
8. Remove excess fluid and incubate with primary antibody in the humidity chamber 
overnight at 4°C or 2 hr at room temperature. 
 
Day two (approx. 2-2.5 hr) 
 
9. Rinse with PBS (3x for 3 min each). 
10. Incubate with protein blocking solution for 5-10 min. 
11. Remove excess fluid and incubate with HRP-conjugated secondary antibody in the 
humidity chamber for 60 min at room temperature. 
12. Rinse with PBS (3x for 3 min each). 
13. Remove excess liquid and add DAB. Incubate for 5-20 min at room temperature. 
Check reaction under a bright-field microscope and determine when to stop reaction. 
14. Rinse with distilled water. 
15. Rinse with Brij solution. 
16. Remove excess fluid and add a drop of Gill's hematoxylin for a few seconds.  
17. Rinse with distilled water to remove excess hematoxylin. 
18. Add PBS for about 1 min. 
19. Rinse with distilled water and air dry slides. 
20. Remove rubber cement rings, if used. Mount sections with Universal Mount and dry 
on a 56°C hot plate. 
 
Notes 
 
 Acetone:chloroform (1:1) can be used in step 1 as an additional fixation. Fix in 
acetone, acetone:chloroform, acetone for 5 min each. 
 The primary antibody dilution is 1:100. 
 The secondary antibody dilution is 1:50. 
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A.7 EDC-MEDIATED GMHA-PEPTIDE CONJUGATIONS 
 
Reactions mediated by N-ethyl-N-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) are commonly used for conjugating carboxylates and amines [1]. However, EDC 
reactions are highly pH-dependent and an excess of amine is required for high levels of 
modification [1,2]. Furthermore, EDC-mediated reactions with HA are particularly 
challenging, as they readily convert HA's carboxylate to an unreactive N-acylurea [2,3,4]. 
 
References: 
1. Bioconjugate Techniques by Hermanson (1996).  
2. JBMR (1999) 47:152-69 
3. Carbohydr Res (1982) 105:69-85 
4. Bioconj Chem (1991) 2:232-4
 
Materials 
 
GMHA (or HA) 
Peptide in solution 
EDC* (MW 191.71)     Aldrich 16-146-2 
N-hydroxysuccinimide* (NHS, MW 115.1)  Sigma H7377 
1-Hydroxybenzotriazole hydrate (HOBt, MW 135.1) Peptides International 814421 
Dimethylsulfoxide (DMSO) 
2-Morpholinoethanesulfonic acid (MES, MW 195.2) Sigma M8250 
Sodium Chloride (NaCl) 
Dialysis tubing, 7000 MWCO    Pierce 68700 
 
* Carbodiimides and succinimides are extremely unstable in the presence of water. 
Solutions should be freshly prepared. EDC should be stored under N2 or Ar in a 
desiccator at –20°C. NHS and HOBt should be stored with desiccant.  
 
0.1 M MES buffer, 0.3 M NaCl, pH 5.5-7.5 
 
Dissolve 3.9 g MES and 3.5 g NaCl in 180 ml ddI. Adjust pH. Fill to 200 ml. Filter 
sterilize. 
 
Conjugation reaction 
 
1. Dissolve GMHA in MES buffer at 1 mg/ml overnight. 
2. Make a 20 mg/ml solution of NHS in ddI or HOBt in 50:50 DMSO:ddI. 
3. Add the NHS or HOBt to the GMHA solution at a molar ratio of 0.25 - 1.0 mol per 
mol of GMHA carboxylate groups. Mix at room temperature for 5 min. 
4. Meanwhile, make a 20 mg/ml solution of EDC in ddI. 
5. Add the EDC solution to the GMHA solution and mix at R/T for 5 min. 
6. Add the peptide solution, readjust pH, and mix at room temperature 2 h. 
7. Dialyze overnight against a 20-fold greater volume of ddI than the reaction volume. 
8. Lyophilize and store with desiccant at –20C.  
9. Use the ninhydrin assay to measure the extent of peptide conjugation. 
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A.8 ACRYLATED PEG-PEPTIDES 
 
 This protocol outlines how to conjugate an acrylated polyethylene glycol (PEG) to a 
peptide for photoinitiated conjugation reactions. 
 Adapted from JBMR 39:266 (1998) and JBMR 60:86 (2002) 
 
Materials 
 
Sodium bicarbonate 
Peptide      (e.g., hexaglycine, Sigma G5630) 
Acryloyl-PEG-N-hydroxysuccinimide ester (Acrl-PEG-NHS)  
 Nektar Therapeutics 012A0F02  
Dialysis membrane, 1000 MWCO  Spectra/Por 131090 
 
50 mM sodium bicarbonate buffer, pH 8.5 
Add 2.1 g sodium bicarbonate to 480 ml ddI. Adjust pH to 8.3. Add ddI up to 500 ml. 
Filter sterilize. 
 
Hexaglycine aliquots, 10 mg/ml in 1 M HCl 
1. Dissolve 100 mg hexaglycine in 10 ml 1M HCl and warm to 37-45°C to dissolve.  
2. Once aliquots are frozen, the hexaglycine will precipitate out and must be redissolved 
at 37-45°C before use.  
3. For other peptides, see their product information for dissolution and aliquoting 
procedures. 
 
Methods: Conjugation reaction, makes ~0.18 g product 
1. Add 2.24 ml 10 mg/ml hexaglycine stock and 2.24 ml 1M NaOH simultaneously to 
15 ml sodium bicarbonate buffer. (If you add the hexaglycine stock first, the 
bicarbonate will react with the HCl and make fizzy CO2 gas.) 
2. Adjust pH to ~8.0 - 8.5. 
3. Add 0.2 g acryl-PEG-NHS and mix immediately to dissolve. 
4. Mix 2 hr at room temperature. 
5. Dialyze against at least 1 L ddI overnight. 
6. Can verify reaction with MALDI-MS, which is capable of measuring the molecular 
weight of ionizable molecules. MALDI cannot be used to measure the molecular 
weight of acryl-PEG-NHS; all amino acids and peptide sequences are ionizable at 
their termini; many amino acid side chains are also ionizable. 
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A.9 NINHYDRIN ASSAY 
 
 Adapted from Anal Biochem (2001) 292:125-129 and Vaccine (1997) 15:672-8. 
 The ninhydrin assay is a sensitive method for determining the amino acid 
concentration in a hydrolyzed sample. This method provides several advantages over 
the Coomassie blue assay. First, less than 5 µg of sample can be quantified 
(Coomassie blue can only be used for >8 µg/ml solutions). Second, low molecular 
weight peptides can be detected (the lower detection limit for Coomassie blue is 
3000-5000 Da). Finally, insoluble proteins can also be detected (proteins must be in 
solution for the Coomassie blue assay).  
 
Materials 
 
Concentrated HCl (12 M stock) * 
Concentrated NaOH (13.5 M stock prepared) * 
BSA or other standard protein or peptide 
Stannous chloride dihydrate (SnCl2·2H2O) *   Lancaster 9080  
Ethylene glycol *,^ 
Ninhydrin        Sigma N6014 
96-well plate 
Sealing tape for 96-well plate      Costar 3095 or 6570 
 
* Hazardous materials – be sure to read MSDS sheets and wear protective equipment 
^ Sensitive to ambient air, store under N2 or Ar 
 
0.1 M citric acid buffer, pH 4.7 
Dissolve 19.21 g citric acid in 0.9 L ddI. Adjust pH to 4.5. Add volume up to 1 L with 
ddI. Filter sterilize. 
 
Hydrolyzed BSA or peptide standard 
1. Dissolve BSA (or other standard) in 13.5M NaOH at about 1 mg/ml in an autoclave-
safe glass vial. 
2. Autoclave at 125°C for at least 40 minutes. 
3. Measure the sample volume after autoclaving and add water if volume is less than 
original volume.  
4. Carefully and dropwise, add concentrated HCl in equimolar amount to NaOH to 
neutralize the base. (A salt precipitate may form, which does not seem to affect the 
results.) 
5. Make sure the solution is well mixed and then prepare ~10 ml of 50 µg/ml standard 
in citric acid buffer. 
6. Check the pH to make sure it is in the range of 2-9. Adjust pH if necessary. 
7. Recalculate the final concentration of standard, if necessary. 
8. Prepare standard solutions to cover the range 10 – 50 µg/ml. Use citric acid buffer to 
prepare the dilutions.  
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4N acetate buffer  
Dissolve 54.4 g sodium acetate in 100 ml acetic acid. Add up to 500 ml total volume with 
ddI. pH should be ~5.5 (assay will still work if pH is up to ~8). 
 
Stannous chloride solution 
Add 100 mg SnCl2·2H2O to 1 ml ethylene glycol, mix well. Solution will be cloudy or 
have a fine suspension. Mix well before use. 
 
Ninhydrin reagent 
1. Add 200 mg ninhydrin to 7.5 ml ethylene glycol and 2.5 ml 4N acetate buffer, mix 
well on stir plate. 
2. Add 250 µl freshly prepared stannous chloride solution with stirring. Solution will 
turn dark purple and then light red. Keep on stir plate until pale red color develops 
(~5-10 minutes). 
3. Store under N2 or Ar at room temperature for a few days (or while still red in color).   
 
Methods 
 
1. Hydrolyze sample using same procedure as hydrolyzed standards.  
2. Dilute samples to fall within the 10 – 50 µg/ml range. 
3. Start a water bath heating to 100°C. The bath must be large enough to hold a well 
plate. 
4. In a 96-well plate, add samples and hydrolyzed BSA standards, 80 µl per well, in 
triplicate.  
5. Add 80 µl per well of ninhydrin reagent.  
6. Cover well plate with sealing tape. This will help prevent sample spilling and 
evaporation while the plate is in the boiling water bath. 
7. Check the water bath to make sure that the temperature is 95-100°C and that the 
water is not boiling rapidly. Using tongs, place the well plate in the water bath. 
Incubate for 10 minutes, checking the bath periodically.  
8. Remove the well plate from the bath, dry the bottom, and read the absorbance of the 
wells at 595 nm on a plate reader.  
9. Using the standards as a calibration curve, calculate the original amino acid 
concentration in the samples. 
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